ifosfamide has been researched along with Osteogenic Sarcoma in 261 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Lay abstract Traditional treatment for osteosarcoma (bone cancer) includes drugs that cause cell damage, such as ifosfamide and etoposide." | 9.41 | OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. ( Bautista, F; Campbell-Hewson, Q; Gaspar, N; Huang, J; Okpara, CE, 2021) |
| "In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum)." | 9.27 | Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. ( Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C, 2018) |
| "This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy." | 9.22 | Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. ( Chen, XT; Christ, AB; Hu, JS; Luminais, SN; Ma, B; Roman, D, 2022) |
| "Studies of baseline prognostic factors in patients with localized osteosarcoma treated without high dose methotrexate are limited." | 9.20 | Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. ( Bakhshi, S; Batra, A; Khan, SA; Nataraj, V; Rastogi, S; Sharma, MC; Vishnubhatla, S, 2015) |
| "High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)." | 9.19 | Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014) |
| "We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity." | 9.16 | Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. ( Alberghini, M; Bacci, G; Bertulli, R; Bisogno, G; Capanna, R; Cefalo, G; Comandone, A; Fagioli, F; Ferrari, S; Linari, A; Palmerini, E; Parafioriti, A; Picci, P; Ruggieri, P; Tamburini, A, 2012) |
| "Thirteen patients, median age 18 (range: 8-34), with metastatic or axial-skeletal osteosarcoma were treated with ifosfamide 2." | 9.12 | A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. ( Lewis, I; McTiernan, A; Meyer, T; Michelagnoli, MP; Whelan, JS, 2006) |
| "The SFOP-OS94 randomised multi-centre trial was designed to determine whether preoperative chemotherapy regimen combining high-dose methotrexate courses and etoposide-ifosfamide could improve the proportion of good histologic response (5% viable cells) compared to a regimen based on high-dose methotrexate and doxorubicin, in children/adolescents with localised high-grade limb osteosarcoma." | 9.12 | SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. ( Brugières, L; Dupoüy, N; Entz-Werlé, N; Gentet, JC; Guinebretière, JM; Kalifa, C; Le Deley, MC; Marec-Bérard, P; Pacquement, H; Pichon, F; Schmitt, C; Tabone, MD; Vanel, D, 2007) |
| "The combination of cisplatin, ifosfamide and epirubicin is an active, reasonably well-tolerated regimen without grade 3 or 4 cardiac toxicity in patients with nonmetastatic extremity osteosarcoma and deserves further investigation in the context of prospective phase III trials." | 9.12 | A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. ( Atalar, AC; Basaran, M; Bavbek, ES; Bilgic, B; Eralp, L; Onat, H; Ozger, H; Saglam, S; Sakar, B, 2007) |
| "The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis." | 9.11 | A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. ( Benjamin, RS; Champlin, R; Donato, M; Lewis, VO; Lin, PP; Papadopolous, N; Patel, SR; Raymond, AK; Seong, CM; Yasko, AW, 2004) |
| "The combination of irinotecan (daily for 5 days for 2 consecutive weeks) and ifosfamide (daily on days 1 through 3) was investigated in children with osteosarcoma." | 9.11 | Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. ( Crews, KR; Daw, NC; Liu, T; Rodriguez-Galindo, C; Santana, VM; Stewart, CF, 2004) |
| "To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS)." | 9.11 | Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. ( Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R, 2005) |
| "To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity." | 9.11 | Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( Alvegard, TA; Bacci, G; Bernini, G; Bertoni, F; Böhling, T; Brosjö, O; Capanna, R; Comandone, A; Del Prever, AB; Ferrari, S; Longhi, A; Mercuri, M; Müller, C; Picci, P; Ruggieri, P; Saeter, G; Smeland, S; Tienghi, A; Wiebe, T, 2005) |
| " In this study, 19 male and 13 female patients with osteosarcoma, ages 9 to 45 years, treated with chemotherapy, received intravenous tropisetron 5 mg plus dexamethasone 8 mg every 12 hours during the first two cycles of the preoperative treatment: cisplatin 120 mg/m2 over 48 hours followed by Adriamycin 75 mg/m2 delivered in 24 hours and continuous infusion of ifosfamide 15 g/m2 over 120 hours." | 9.10 | Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours. ( Bacci, G; Beghelli, C; Biolchini, A; Forni, C; Loro, L; Mazzei, T; Tremosini, M; Triggiani, A, 2003) |
| "The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma." | 9.10 | Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002) |
| "With the intention of starting an international protocol between Italy and Scandinavia on neoadjuvant treatment of extremity osteosarcoma using the four active drugs at maximum doses (doxorubicin 75 mg/m2 pre-operatively, and 90 mg/m2 post-operatively, cisplatin 120 mg/m2, methotrexate 12 g/m2, and ifosfamide 15 g/m2), a single center (the Rizzoli institute) performed a pilot study to closely monitor toxicity, safety, and tumor necrosis." | 9.10 | High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. ( Alvegard, TA; Bacci, G; Briccoli, A; Donati, D; Ferrari, S; Forni, C; Lari, S; Longhi, A; Manfrini, M; Mercuri, M; Picci, P; Saeter, G, 2002) |
| "This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma." | 9.08 | Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. ( Ayala, AG; Cantor, AB; Ferguson, WS; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1995) |
| "The aim of this phase II study was to determine the efficacy of high-dose ifosfamide with moderate dose etoposide in childhood osteosarcoma." | 9.08 | Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. ( Avet-Loiseau, H; Berger, C; Bernard, JL; Brunat-Mentigny, M; De Lumley, L; Demaille, MC; Gentet, JC; Kalifa, C; Pacquement, H; Pein, F; Pillon, P; Sariban, E; Schmitt, C, 1997) |
| "This Phase II study evaluated doxorubicin, dacarbazine, ifosfamide, and mesna (MAID) in adults with inoperable or metastatic Ewing's sarcoma, rhabdomyosarcoma, or osteosarcoma." | 9.08 | A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. ( Antman, K; Baker, LH; Balcerzak, SP; Clamon, GH; Crowley, J; Kempf, RA; Weiss, RB, 1998) |
| " The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma." | 9.08 | Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. ( Brunat-Mentigny, M; Cochat, P; Dubourg, L; Hadj-Aïssa, A; Koch Nogueira, PC; Schell, M, 1998) |
| "Nine patients with osteosarcoma were treated by chemotherapy combined with caffeine and surgery." | 9.07 | Effect of chemotherapy combined with caffeine for osteosarcoma. ( Baba, H; Tomita, K; Tsuchiya, H; Ueda, Y; Yasutake, H; Yokogawa, A, 1992) |
| "The efficacy of ifosfamide-based chemotherapy in the treatment of osteosarcoma has been investigated; however, results are inconsistent." | 8.91 | Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis. ( Cai, GP; Ding, GM; Fan, XL; Zhu, LL, 2015) |
| "To assess testicular function after standard dose ifosfamide, we evaluated 6 young adult osteosarcoma survivors (median age at diagnosis, 16." | 8.90 | Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( Diller, L; Duffey-Lind, E; Ebb, D; Grier, H; Kenney, LB; Sklar, CA, 2014) |
| "Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas." | 8.78 | The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990) |
| "The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas." | 8.77 | The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989) |
| "Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings." | 8.02 | Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021) |
| "Current treatment of high-grade osteosarcoma consists of preoperative chemotherapy, typically using some combination of doxorubicin, cisplatin, ifosfamide, and/or high-dose methotrexate followed by surgical resection." | 7.91 | Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation. ( Savani, M; Skubitz, KM, 2019) |
| "All treatment naive consecutive patients of osteosarcoma were prospectively treated on a novel institutional regimen (named OGS-12) comprising of eight sequential doublets of the following drugs: doxorubicin, cisplatin and ifosfamide in four courses each, given in the neoadjuvant and adjuvant settings." | 7.85 | Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. ( Bajpai, J; Banavali, SD; Chandrakanth, MV; Chandrasekharan, A; Ghosh, J; Gupta, S; Khan, A; Khurana, S; Rekhi, B; Simha, V; Talreja, V; Vora, T, 2017) |
| "Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide)." | 7.83 | Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Gebhardt, MC; Goorin, AM; Grier, HE; Healey, JH; Krailo, MD; Lipshultz, SE; Meyers, PA; Sato, JK; Schwartz, CL; Steinherz, LJ; Teot, LA; Wexler, LH, 2016) |
| "Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma." | 7.81 | Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? ( Lin, F; Shen, Z; Tang, L; Yao, Y; Yu, W, 2015) |
| "The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma." | 7.81 | Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015) |
| "In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles (PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells." | 7.81 | Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015) |
| "Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide." | 7.80 | Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014) |
| "Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma." | 7.80 | Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014) |
| "This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma." | 7.80 | Ifosfamide-containing regimens for treating patients with osteosarcomas. ( Dong, YG; Jiang, XM; Li, YY; Ma, YB; Xu, G, 2014) |
| "A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)." | 7.80 | Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014) |
| "To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University." | 7.79 | Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013) |
| "The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively." | 7.79 | Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. ( He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H, 2013) |
| "The objective of this study was to investigate the efficacy and toxic side effects of two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide on treating Chinese osteosarcoma patients." | 7.77 | Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. ( Dong, Y; Lin, F; Shen, Z; Sun, Y; Tang, L; Wang, Q; Yao, Y; Yu, W; Zheng, S, 2011) |
| "This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II." | 7.76 | Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. ( Chen, P; Lin, F; Sun, Y; Wang, Z; Yao, Y; Zhao, H, 2010) |
| "The cytotoxic effect of palifosfamide lysine was studied in osteosarcoma (OS), Ewing's sarcoma (ES) and rhabdomyosarcoma (RMS) cell lines using the MTT assay." | 7.75 | Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. ( Gorlick, R; Hingorani, P; Kolb, EA; Lin, J; Piperdi, S; Pressman, L; Zhang, W, 2009) |
| "In an attempt to find leads to such markers, we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide, doxorubicin, and cisplatin." | 7.75 | Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. ( Bruheim, S; Fodstad, O; Ju, J; Xi, Y, 2009) |
| " Flow cytometric analyses by means of annexin-V and propidium iodide double staining and immunofluorescence staining of active caspase-3 revealed that cells subjected to a lethal dose of chloroacetaldehyde displayed features characteristic of necrosis and that caspase-3 was not activated in response to chloroacetaldehyde." | 7.74 | Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. ( Fujimoto, Y; Sakurai, K; Takahashi, K; Tanaka, H, 2007) |
| " We report a 9-year-old boy with osteosarcoma who experienced 2 episodes of pancreatitis 1 day and 48 days after infusion of ifosfamide (IFOS), respectively." | 7.74 | Acute pancreatitis associated with ifosfamide. ( Hung, GY; Hung, MC; Lin, PC; Tien, YC; Tiu, CM, 2007) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 7.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| "The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable model of osteosarcoma." | 7.73 | Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. ( Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP, 2005) |
| "Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS)." | 7.73 | Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. ( Duan, X; Jia, SF; Kleinerman, ES; Koshkina, N, 2006) |
| "A 16-year-old girl with a distal femur osteosarcoma became pain-free with the first treatment of methotrexate 12." | 7.72 | Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. ( Cohen, IJ, 2003) |
| "To determine the activity of carboplatin/ifosfamide in patients with previously untreated osteosarcoma and to estimate patient outcomes after a multiagent chemotherapy protocol that eliminated cisplatin." | 7.71 | Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. ( Fletcher, BD; Harper, J; Jenkins, JJ; Mahmoud, HH; Marina, NM; Meyer, WH; Neel, M; Pappo, AS; Parham, DM; Poquette, CA; Pratt, CB; Rao, BN, 2001) |
| "Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor." | 7.70 | [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998) |
| "This prospective study was designed to test the activity of an ifosfamide-etoposide (VP-16) regimen on poor-risk, nonmetastatic, osteogenic sarcoma." | 7.70 | Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma. ( Ben Arush, MW; Drumea, K; Haim, N; Kuten, A; Meller, I; Moses, M; Stein, ME, 1998) |
| "Ifosfamide and cisplatin are active agents that are currently used in the treatment of osteosarcoma." | 7.70 | Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. ( Arndt, C; Hawkins, D; Liedtke, R; Miser, J; Morgenstern, B; Wilson, D, 1999) |
| "We attempted to ascertain renal, hematologic, and neurologic tolerance to ifosfamide (IFX) in pediatric patients previously treated with large single and cumulative doses of cis-Diamminedichloroplatinum-II (CDP) for osteosarcoma (OS)." | 7.69 | Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations. ( Canpolat, C; Jaffe, N; Pearson, P; Robertson, R, 1996) |
| " A 16-year-old girl with metastatic osteosarcoma experienced recurrent bouts of symptomatic pancreatitis 24 hours after treatment with ifosfamide administered as a single agent." | 7.69 | Acute pancreatitis after ifosfamide therapy. ( Adamson, PC; Balis, FM; Blaney, SM; Izraeli, S, 1994) |
| "From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 7.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 7.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "The relationship between the serum concentration of methotrexate and the prognosis has been studied in 108 patients with osteosarcoma of the extremities treated from September 1986 to December 1989 at the Chemotherapy Department of Rizzoli Hospital." | 7.68 | Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. ( Bacci, G; Battistini, A; Ferrari, S; Orlandi, M; Puggioli, C; Sassoli, V; Strazzari, S, 1993) |
| "To improve the accuracy of magnetic resonance imaging (MRI) in evaluating the response of osteosarcomas to preoperative chemotherapy, the authors developed a technique of mapping tumor necrosis and viability by quantitating slope values of gadolinium-DTPA (Gd-DTPA) uptake on dynamic fast low-angle shot (FLASH) images." | 7.68 | Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. ( Fairclough, DL; Fletcher, BD; Hanna, SL; Le, AH; Meyer, WH; Parham, DM, 1992) |
| "A 13-year-old boy with unresectable pulmonary metastatic osteosarcoma, which was refractory to high dose methotrexate, adriamycin, cisplatin and combination of bleomycin, cyclophosphamide and actinomycin D, was treated by aggressive chemotherapy including the combination of ifosfamide (1 g/m2 x day 1-4), Carboplatin (100 mg/m2 x day 1-4) and Vindesine (4 mg/m2 x day 1)." | 7.68 | [Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report]. ( Fujita, H; Ishimoto, K; Kiyokawa, N; Kyo, K; Mizuno, T; Takada, K; Yabuta, K, 1991) |
| "In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1." | 7.67 | High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985) |
| " The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome." | 6.71 | High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ( Crews, KR; Daw, NC; Link, MP; Liu, T; Meyer, WH; Panetta, JC; Rodriguez-Galindo, C; Tan, M, 2004) |
| "Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s." | 6.52 | Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials. ( Lai, Z; Lin, Y; Mo, Y; Su, W; Wu, F; Wu, J; Yang, Z, 2015) |
| "Lay abstract Traditional treatment for osteosarcoma (bone cancer) includes drugs that cause cell damage, such as ifosfamide and etoposide." | 5.41 | OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma. ( Bautista, F; Campbell-Hewson, Q; Gaspar, N; Huang, J; Okpara, CE, 2021) |
| "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments." | 5.37 | Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011) |
| "The effect of immunotherapy with interleukin-18 (IL-18) in combination with preoperative chemotherapy on the postoperative progression of pulmonary metastasis was examined using a spontaneous pulmonary metastasis model of mouse osteosarcoma." | 5.35 | Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. ( Futani, H; Hata, M; Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamanegi, K, 2009) |
| "In most countries, reference chemotherapy for osteosarcoma is MAP regimen (M = high-dose methotrexate, AP = doxorubicin-cisplatinum)." | 5.27 | Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. ( Bompas, E; Bouvier, C; Brisse, HJ; Brugieres, L; Castex, MP; Cheurfa, N; Corradini, N; Delaye, J; Entz-Werlé, N; Gaspar, N; Gentet, JC; Italiano, A; Le Deley, MC; Lervat, C; Marec-Berard, P; Mascard, E; Occean, BV; Pacquement, H; Piperno-Neumann, S; Redini, F; Saumet, L; Schmitt, C; Tabone, MD; Verite-Goulard, C, 2018) |
| "We examined the clinical significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on the Glutaminase 1 gene (GLS1) expression." | 5.27 | Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression. ( Li, H; Li, X; Sun, XH; Yan, XF; Zhang, SP, 2018) |
| "This is the first instance of tumor lysis syndrome described in a patient with osteosarcoma undergoing ifosfamide monotherapy." | 5.22 | Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature. ( Chen, XT; Christ, AB; Hu, JS; Luminais, SN; Ma, B; Roman, D, 2022) |
| "Patients with resectable osteosarcoma aged ≤40 years were treated with the MAP regimen, comprising pre-operatively of two 5-week cycles of cisplatin 120 mg/m(2), doxorubicin 75 mg/m(2), methotrexate 12 g/m(2) × 2 (MAP) and post-operatively two further cycles of MAP and two cycles of just MA." | 5.20 | EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. ( Anninga, J; Bernstein, M; Bielack, SS; Böhling, T; Butterfass-Bahloul, T; Calaminus, G; Capra, M; Deffenbaugh, C; Dhooge, C; Eriksson, M; Flanagan, AM; Gelderblom, H; Goorin, A; Gorlick, R; Gosheger, G; Grimer, RJ; Hall, KS; Helmke, K; Hogendoorn, PC; Hook, JM; Jovic, G; Jundt, G; Kager, L; Krailo, M; Kuehne, T; Lau, CC; Letson, GD; Marina, N; Meyer, J; Meyers, PA; Morris, C; Mottl, H; Nadel, H; Nagarajan, R; Randall, RL; Schomberg, P; Schwarz, R; Smeland, S; Sydes, MR; Teot, LA; Whelan, JS, 2015) |
| "Studies of baseline prognostic factors in patients with localized osteosarcoma treated without high dose methotrexate are limited." | 5.20 | Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. ( Bakhshi, S; Batra, A; Khan, SA; Nataraj, V; Rastogi, S; Sharma, MC; Vishnubhatla, S, 2015) |
| "High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)." | 5.19 | Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014) |
| "To improve the treatment results of patients with locally advanced osteosarcoma with large volume using neoadjuvant chemotherapy (NACT) (ifosfamide at a dose of 18 g/ml) and planning of organ-conserving surgery by evaluating the state of tumor pseudocapsule." | 5.17 | Treatment of large osteosarcoma in children: new approach. ( Golovko, TS; Gulak, LO; Kobys, VL; Konovalenko, VF; Matyushok, OF; Repinа, NV; Tarasova, TO; Zaharycheva, EV, 2013) |
| "We compared two chemotherapy regimens that included methotrexate (MTX), cisplatin (CDP), and doxorubicin (ADM) with or without ifosfamide (IFO) in patients with nonmetastatic osteosarcoma of the extremity." | 5.16 | Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. ( Alberghini, M; Bacci, G; Bertulli, R; Bisogno, G; Capanna, R; Cefalo, G; Comandone, A; Fagioli, F; Ferrari, S; Linari, A; Palmerini, E; Parafioriti, A; Picci, P; Ruggieri, P; Tamburini, A, 2012) |
| "To compare three-drug chemotherapy with cisplatin, doxorubicin, and methotrexate with four-drug chemotherapy with cisplatin, doxorubicin, methotrexate, and ifosfamide for the treatment of osteosarcoma." | 5.13 | Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. ( Bernstein, ML; Betcher, D; Ferguson, WS; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, M; Healey, JH; Kleinerman, E; Krailo, MD; Link, MP; Meyers, PA; Nadel, H; Nieder, M; Schwartz, CL; Siegal, GP; Weiner, MA; Wells, RJ; Womer, RB, 2008) |
| "Thirteen patients, median age 18 (range: 8-34), with metastatic or axial-skeletal osteosarcoma were treated with ifosfamide 2." | 5.12 | A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma. ( Lewis, I; McTiernan, A; Meyer, T; Michelagnoli, MP; Whelan, JS, 2006) |
| "The outcome of patients with metastatic osteosarcoma treated in two consecutive trials from 1986 to 1997 was analyzed to evaluate the efficacy of carboplatin-based multiagent chemotherapy and to identify prognostic factors." | 5.12 | Metastatic osteosarcoma. ( Billups, CA; Cain, AM; Daw, NC; Jenkins, JJ; McCarville, MB; Meyer, WH; Neel, MD; Rao, BN; Rodriguez-Galindo, C, 2006) |
| "The SFOP-OS94 randomised multi-centre trial was designed to determine whether preoperative chemotherapy regimen combining high-dose methotrexate courses and etoposide-ifosfamide could improve the proportion of good histologic response (5% viable cells) compared to a regimen based on high-dose methotrexate and doxorubicin, in children/adolescents with localised high-grade limb osteosarcoma." | 5.12 | SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. ( Brugières, L; Dupoüy, N; Entz-Werlé, N; Gentet, JC; Guinebretière, JM; Kalifa, C; Le Deley, MC; Marec-Bérard, P; Pacquement, H; Pichon, F; Schmitt, C; Tabone, MD; Vanel, D, 2007) |
| "The combination of cisplatin, ifosfamide and epirubicin is an active, reasonably well-tolerated regimen without grade 3 or 4 cardiac toxicity in patients with nonmetastatic extremity osteosarcoma and deserves further investigation in the context of prospective phase III trials." | 5.12 | A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. ( Atalar, AC; Basaran, M; Bavbek, ES; Bilgic, B; Eralp, L; Onat, H; Ozger, H; Saglam, S; Sakar, B, 2007) |
| "The objective of this study was to estimate the time to treatment failure and survival rate of the three-drug combination of doxorubicin, cisplatin, and ifosfamide as primary and postoperative, adjunctive treatment for teenagers and adults with osteosarcoma (OS)." | 5.11 | Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139. ( Antman, K; Biermann, JS; Budd, GT; Lanier, KS; Lucas, DR; Meyers, FJ; Muler, J; Rankin, C; Ryan, JR; Zalupski, MM, 2004) |
| "The authors evaluated the efficacy and toxicity of cisplatin, ifosfamide, and doxorubicin with peripheral blood stem cell (PBSC) support in adult patients with osteosarcomas and variants with a poor prognosis." | 5.11 | A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis. ( Benjamin, RS; Champlin, R; Donato, M; Lewis, VO; Lin, PP; Papadopolous, N; Patel, SR; Raymond, AK; Seong, CM; Yasko, AW, 2004) |
| "The combination of irinotecan (daily for 5 days for 2 consecutive weeks) and ifosfamide (daily on days 1 through 3) was investigated in children with osteosarcoma." | 5.11 | Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma. ( Crews, KR; Daw, NC; Liu, T; Rodriguez-Galindo, C; Santana, VM; Stewart, CF, 2004) |
| "To determine whether the addition of ifosfamide and/or muramyl tripeptide (MTP) encapsulated in liposomes to cisplatin, doxorubicin, and high-dose methotrexate (HDMTX) could improve the probability for event-free survival (EFS) in newly diagnosed patients with osteosarcoma (OS)." | 5.11 | Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. ( Bernstein, ML; Betcher, D; Conrad, E; Ferguson, W; Gebhardt, M; Goorin, AM; Grier, H; Harris, MB; Healey, J; Huvos, A; Kleinerman, ES; Krailo, M; Link, M; Meyers, PA; Montebello, J; Nadel, H; Nieder, M; Sato, J; Schwartz, CL; Siegal, G; Weiner, M; Wells, R; Wold, L; Womer, R, 2005) |
| "To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity." | 5.11 | Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( Alvegard, TA; Bacci, G; Bernini, G; Bertoni, F; Böhling, T; Brosjö, O; Capanna, R; Comandone, A; Del Prever, AB; Ferrari, S; Longhi, A; Mercuri, M; Müller, C; Picci, P; Ruggieri, P; Saeter, G; Smeland, S; Tienghi, A; Wiebe, T, 2005) |
| " In this study, 19 male and 13 female patients with osteosarcoma, ages 9 to 45 years, treated with chemotherapy, received intravenous tropisetron 5 mg plus dexamethasone 8 mg every 12 hours during the first two cycles of the preoperative treatment: cisplatin 120 mg/m2 over 48 hours followed by Adriamycin 75 mg/m2 delivered in 24 hours and continuous infusion of ifosfamide 15 g/m2 over 120 hours." | 5.10 | Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours. ( Bacci, G; Beghelli, C; Biolchini, A; Forni, C; Loro, L; Mazzei, T; Tremosini, M; Triggiani, A, 2003) |
| "The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma." | 5.10 | Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002) |
| "With the intention of starting an international protocol between Italy and Scandinavia on neoadjuvant treatment of extremity osteosarcoma using the four active drugs at maximum doses (doxorubicin 75 mg/m2 pre-operatively, and 90 mg/m2 post-operatively, cisplatin 120 mg/m2, methotrexate 12 g/m2, and ifosfamide 15 g/m2), a single center (the Rizzoli institute) performed a pilot study to closely monitor toxicity, safety, and tumor necrosis." | 5.10 | High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. ( Alvegard, TA; Bacci, G; Briccoli, A; Donati, D; Ferrari, S; Forni, C; Lari, S; Longhi, A; Manfrini, M; Mercuri, M; Picci, P; Saeter, G, 2002) |
| "Patients with nonmetastatic osteosarcoma of the extremity were preoperatively treated with high-dose methotrexate, cisplatin, and doxorubicin (ADM)." | 5.09 | Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. ( Bacci, G; Bertoni, F; Campanacci, M; Casadei, R; Fabbri, N; Ferrari, S; Forni, C; Longhi, A; Picci, P; Ruggieri, P; Versari, M, 2000) |
| "A phase IIb trial using liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE) in combination with ifosfamide (IFX) for patients with relapsed osteosarcoma was undertaken to determine (a) the tolerability of the combination therapy, (b) if L-MTP-PE increased the toxicity of IFX, and (c) whether IFX altered or suppressed the in vivo immune response to L-MTP-PE." | 5.08 | Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation. ( Gano, JB; Jaffe, N; Jia, SF; Kleinerman, ES; Meyers, PA; Raymond, AK, 1995) |
| "This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma." | 5.08 | Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. ( Ayala, AG; Cantor, AB; Ferguson, WS; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1995) |
| "Ten patients (three males and seven females) were treated for sarcoma with high-dose ifosfamide (IFO) according to a 4 g/m2 1 h i." | 5.08 | Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans. ( Lokiec, F; Santoni, J; Tubiana-Hulin, M; Weill, S, 1996) |
| "The aim of this phase II study was to determine the efficacy of high-dose ifosfamide with moderate dose etoposide in childhood osteosarcoma." | 5.08 | Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. ( Avet-Loiseau, H; Berger, C; Bernard, JL; Brunat-Mentigny, M; De Lumley, L; Demaille, MC; Gentet, JC; Kalifa, C; Pacquement, H; Pein, F; Pillon, P; Sariban, E; Schmitt, C, 1997) |
| "This Phase II study evaluated doxorubicin, dacarbazine, ifosfamide, and mesna (MAID) in adults with inoperable or metastatic Ewing's sarcoma, rhabdomyosarcoma, or osteosarcoma." | 5.08 | A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. ( Antman, K; Baker, LH; Balcerzak, SP; Clamon, GH; Crowley, J; Kempf, RA; Weiss, RB, 1998) |
| " The aim of the present study was to assess long-term renal function in children and adolescents who received at-risk chemotherapy, including cisplatin, ifosfamide, and methotrexate, to treat an osteosarcoma." | 5.08 | Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma. ( Brunat-Mentigny, M; Cochat, P; Dubourg, L; Hadj-Aïssa, A; Koch Nogueira, PC; Schell, M, 1998) |
| "In an effort to intensify osteosarcoma therapy, systemic ifosfamide was added pre- and postoperatively to an already aggressive three-drug regimen." | 5.08 | Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. ( Bielack, SS; Bieling, P; Delling, G; Epler, D; Fuchs, N; Graf, N; Heise, U; Jürgens, H; Körholz, D; Kotz, R; Salzer-Kuntschik, M; Weinel, P; Werner, M; Winkler, K, 1998) |
| "To estimate the duration of survival (S) of patients with metastatic osteosarcoma (MOS) at diagnosis treated with a multiagent, ifosfamide-containing chemotherapeutic and surgical regimen and to evaluate the toxicity of this regimen." | 5.08 | Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. ( Ayala, A; Ferguson, WS; Gieser, P; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1998) |
| "Nine patients with osteosarcoma were treated by chemotherapy combined with caffeine and surgery." | 5.07 | Effect of chemotherapy combined with caffeine for osteosarcoma. ( Baba, H; Tomita, K; Tsuchiya, H; Ueda, Y; Yasutake, H; Yokogawa, A, 1992) |
| "The efficacy of ifosfamide-based chemotherapy in the treatment of osteosarcoma has been investigated; however, results are inconsistent." | 4.91 | Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis. ( Cai, GP; Ding, GM; Fan, XL; Zhu, LL, 2015) |
| "We observed a correlation of higher planned methotrexate total dosage and DI with better treatment outcomes in osteosarcoma patients." | 4.90 | Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years. ( Li, B; Li, H; Li, Y; Sun, L; Ye, Z; Zhang, J, 2014) |
| "To assess testicular function after standard dose ifosfamide, we evaluated 6 young adult osteosarcoma survivors (median age at diagnosis, 16." | 4.90 | Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( Diller, L; Duffey-Lind, E; Ebb, D; Grier, H; Kenney, LB; Sklar, CA, 2014) |
| " The BSTTSG has currently been conducting a Phase III trial, JCOG 0905, to investigate the superiority of the addition of ifosfamide to the standard chemotherapy with methotrexate, cisplatin and doxorubicin for operable, high-grade osteosarcoma." | 4.88 | The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. ( Iwamoto, Y; Tanaka, K, 2012) |
| "At present, patients with nonmetastatic osteosarcoma of the extremity aged less than 40 years have an expected 5-year survival rate of 70% with a chemotherapy regimen based on methotrexate, cisplatin, doxorubicin and ifosfamide." | 4.84 | Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. ( Ferrari, S; Palmerini, E, 2007) |
| "Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma." | 4.82 | Ifosfamide in pediatric solid tumors. ( Bisogno, G; Carli, M; Passone, E; Perilongo, G, 2003) |
| "Using high-dose methotrexate, doxorubicin, and cisplatinum (or BCD) for adjuvant chemotherapy in osteosarcoma of the extremities, we achieved 8-year metastasis-free survival rates of 60-70%." | 4.78 | Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). ( Bielack, SS; Delling, G; Jürgens, H; Kotz, R; Salzer-Kuntschik, M; Winkler, K, 1993) |
| " The most active single agents against osteosarcoma are doxorubicin (overall response rate, 21%), methotrexate (30% to 40%), cisplatin (25%), and ifosfamide (28%)." | 4.78 | Chemotherapy of advanced sarcomas of bone and soft tissue. ( Antman, KH, 1992) |
| "Ifosfamide is an analogue of cyclophosphamide that has been extensively investigated in sarcomas." | 4.78 | The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review. ( Dirix, LY; Van Oosterom, AT, 1990) |
| "The alkylating agent ifosfamide has demonstrated significant activity against advanced sarcomas." | 4.77 | The role of ifosfamide in the treatment of sarcomas. ( Dirix, LY; Van Oosterom, AT, 1989) |
| "We recruited 14 patients with osteosarcoma having acquirable lesions to establish PDX models and examine the sensitivity of nine drugs, including methotrexate (MTX), ifosfamide (IFO), epirubicin, and etoposide." | 4.31 | Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study. ( Chen, G; Ji, C; Li, J; Li, M; Long, Z; Lu, Y; Wang, Q; Wang, Z; Xiang, L; Yu, H, 2023) |
| "Following the 20th week of ifosfamide treatment, the patient's follow-up with the diagnosis of osteosarcoma developed neurological findings." | 4.02 | Ifosfamide induced encephalopathy in a child with osteosarcoma. ( Atay, AA; Demir, ÜF; Malbora, B; Sarbay, H; Yılmaz, G, 2021) |
| "The usefulness of adjuvant chemotherapy for high-grade osteosarcoma was established by two randomized, controlled trials conducted in the 1980s, which used six drugs, doxorubicin, cisplatin, high-dose methotrexate, bleomycin, cyclophosphamide and actinomycin D." | 4.02 | Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group. ( Hiraga, H; Ozaki, T, 2021) |
| "Current treatment of high-grade osteosarcoma consists of preoperative chemotherapy, typically using some combination of doxorubicin, cisplatin, ifosfamide, and/or high-dose methotrexate followed by surgical resection." | 3.91 | Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation. ( Savani, M; Skubitz, KM, 2019) |
| "All treatment naive consecutive patients of osteosarcoma were prospectively treated on a novel institutional regimen (named OGS-12) comprising of eight sequential doublets of the following drugs: doxorubicin, cisplatin and ifosfamide in four courses each, given in the neoadjuvant and adjuvant settings." | 3.85 | Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'. ( Bajpai, J; Banavali, SD; Chandrakanth, MV; Chandrasekharan, A; Ghosh, J; Gupta, S; Khan, A; Khurana, S; Rekhi, B; Simha, V; Talreja, V; Vora, T, 2017) |
| "Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide)." | 3.83 | Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. ( Bernstein, ML; Devidas, M; Gebhardt, MC; Goorin, AM; Grier, HE; Healey, JH; Krailo, MD; Lipshultz, SE; Meyers, PA; Sato, JK; Schwartz, CL; Steinherz, LJ; Teot, LA; Wexler, LH, 2016) |
| "Pirarubicin (THP), a novel anthracycline derivative of doxorubicin (ADM), is effective in treating patients with advanced, relapsed or recurrent high-grade osteosarcoma." | 3.81 | Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? ( Lin, F; Shen, Z; Tang, L; Yao, Y; Yu, W, 2015) |
| "In recent years, chemotherapy with caffeine has manifested potently high efficacy against osteosarcoma, although adverse effects have been observed." | 3.81 | Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles. ( Iwasaki, T; Kidani, T; Masumoto, J; Miura, H; Miyazaki, T; Nakamura, A; Nakata, H; Sakayama, K, 2015) |
| "The aim of this retrospective study was to evaluate the feasibility and efficacy of response to continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for patients with recurrent or refractory osteosarcoma." | 3.81 | Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study. ( He, AN; Huang, YJ; Min, DL; Shen, Z; Sun, YJ; Yao, Y, 2015) |
| "In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles (PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells." | 3.81 | Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015) |
| "Ifosfamide combined with other antineoplastic agents has been effective in the treatment of osteosarcoma, although adverse effects are reported in the increasing use of ifosfamide." | 3.80 | Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury. ( Enokida, H; Hayami, H; Komiya, S; Nagano, S; Nakagawa, M; Nishimura, H; Yokouchi, M, 2014) |
| "Ifosfamide and methotrexate are widely used for the treatment of pediatric osteosarcoma." | 3.80 | Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy. ( Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S, 2014) |
| "We reviewed the records of 50 patients with osteosarcoma who underwent marginal resection following effective preoperative chemotherapy; 18 were treated with the MMIA (high-dose methotrexate (HD-MTX), adriamycin (ADR), ifosfamide (IFO)) and cisplatin (DDP), and 32 patients were treated with the DIA (DDP, ADR and IFO)." | 3.80 | Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes. ( Xu, M; Xu, S; Yu, X, 2014) |
| "This systemic analysis was conducted to evaluate the efficacy and safety of an ifosfamide- containing regimen in treating patients with osteosarcoma." | 3.80 | Ifosfamide-containing regimens for treating patients with osteosarcomas. ( Dong, YG; Jiang, XM; Li, YY; Ma, YB; Xu, G, 2014) |
| "A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)." | 3.80 | Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014) |
| "A 73-year-old man was diagnosed with osteosarcoma and treated with four cycles of preoperative chemotherapy with ifosfamide and doxorubicin followed by wide resection." | 3.79 | Metastasis of osteosarcoma to stomach made clinically evident by hematemesis: a case report. ( Arai, E; Futamura, N; Hirata, A; Ishiguro, N; Kozawa, E; Miyahara, R; Nishida, Y; Tsukushi, S; Tsurudome, I; Urakawa, H, 2013) |
| "To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University." | 3.79 | Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013) |
| "The clinical data of 75 patients who received pirarubicin-based (n = 52) or gemcitabine-docetaxel (n = 23) chemotherapy as a second-line treatment for relapsed and refractory osteosarcoma between January 2005 and September 2011were reviewed retrospectively." | 3.79 | Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience. ( He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H, 2013) |
| "The objective of this study was to investigate the efficacy and toxic side effects of two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide on treating Chinese osteosarcoma patients." | 3.77 | Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. ( Dong, Y; Lin, F; Shen, Z; Sun, Y; Tang, L; Wang, Q; Yao, Y; Yu, W; Zheng, S, 2011) |
| "This study assessed the therapeutic effect of and adverse reactions to pirarubicin (THP) chemotherapy in osteosarcoma patients with lung metastasis, and analyzed the relationship between THP therapeutic effect and expression of p-glycoprotein and topoisomerase-II." | 3.76 | Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis. ( Chen, P; Lin, F; Sun, Y; Wang, Z; Yao, Y; Zhao, H, 2010) |
| "The cytotoxic effect of palifosfamide lysine was studied in osteosarcoma (OS), Ewing's sarcoma (ES) and rhabdomyosarcoma (RMS) cell lines using the MTT assay." | 3.75 | Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. ( Gorlick, R; Hingorani, P; Kolb, EA; Lin, J; Piperdi, S; Pressman, L; Zhang, W, 2009) |
| "In an attempt to find leads to such markers, we have obtained microarray gene expression profiles from a panel of 10 different human osteosarcoma xenografts and related the results to their sensitivity to ifosfamide, doxorubicin, and cisplatin." | 3.75 | Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. ( Bruheim, S; Fodstad, O; Ju, J; Xi, Y, 2009) |
| " Flow cytometric analyses by means of annexin-V and propidium iodide double staining and immunofluorescence staining of active caspase-3 revealed that cells subjected to a lethal dose of chloroacetaldehyde displayed features characteristic of necrosis and that caspase-3 was not activated in response to chloroacetaldehyde." | 3.74 | Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde. ( Fujimoto, Y; Sakurai, K; Takahashi, K; Tanaka, H, 2007) |
| " We report a 9-year-old boy with osteosarcoma who experienced 2 episodes of pancreatitis 1 day and 48 days after infusion of ifosfamide (IFOS), respectively." | 3.74 | Acute pancreatitis associated with ifosfamide. ( Hung, GY; Hung, MC; Lin, PC; Tien, YC; Tiu, CM, 2007) |
| "Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor." | 3.73 | High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. ( Berberoğlu, S; Berrak, SG; Ilhan, IE; Jaffe, N; Pearson, M, 2005) |
| "The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable model of osteosarcoma." | 3.73 | Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. ( Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP, 2005) |
| "Cyclophosphamide (CTX) and ifosfamide (IFX) are alkylating agents used to treat osteosarcoma (OS)." | 3.73 | Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. ( Duan, X; Jia, SF; Kleinerman, ES; Koshkina, N, 2006) |
| "A 16-year-old girl with a distal femur osteosarcoma became pain-free with the first treatment of methotrexate 12." | 3.72 | Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid. ( Cohen, IJ, 2003) |
| "To determine the activity of carboplatin/ifosfamide in patients with previously untreated osteosarcoma and to estimate patient outcomes after a multiagent chemotherapy protocol that eliminated cisplatin." | 3.71 | Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial. ( Fletcher, BD; Harper, J; Jenkins, JJ; Mahmoud, HH; Marina, NM; Meyer, WH; Neel, M; Pappo, AS; Parham, DM; Poquette, CA; Pratt, CB; Rao, BN, 2001) |
| "Between January 1995 and December 1999, 11 patients with synchronous multifocal osteosarcoma (SMO) received neoadjuvant treatment with high-dose methotrexate, cisplatinum, Adriamycin, and ifosfamide." | 3.71 | Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. ( Bacci, G; Bernini, G; Biagini, R; Briccoli, A; Capanna, R; Donati, D; Fabbri, N; Ferrari, S; Longhi, A; Versari, M, 2001) |
| "Ifosfamide, Carboplatin and Etoposide (ICE) therapy was used to treat 4 patients, 2 with refractory osteosarcoma, and one each with relapsed brain tumor and newly diagnosed brain tumor." | 3.70 | [Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)]. ( Agata, H; Fujimoto, T; Hamaguchi, N; Hirota, T; Iwata, A; Katano, N; Kitagawa, S; Kobayashi, S; Konno, K; Sato, T; Sawada, K; Takeuchi, M, 1998) |
| "This prospective study was designed to test the activity of an ifosfamide-etoposide (VP-16) regimen on poor-risk, nonmetastatic, osteogenic sarcoma." | 3.70 | Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma. ( Ben Arush, MW; Drumea, K; Haim, N; Kuten, A; Meller, I; Moses, M; Stein, ME, 1998) |
| "A neoadjuvant chemotherapy protocol (1/93-1/95) for extremity osteosarcoma preoperatively using high-dose methotrexate (HDMTX) as single agent per cycle and three different combinations of other drugs (CDP/IFO,CDP/ADM,IFO/ADM) is reported." | 3.70 | Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study. ( Bacci, G; Bernini, G; Brach del Prever, A; Capanna, R; Cesari, M; Comandone, A; Ferrari, S; Longhi, A; Mercuri, M; Picci, P; Tienghi, A, 1998) |
| " In addition, the chemotherapeutic agent ifosfamide caused a decrease in plasma GPx activity in pediatric osteosarcoma patients." | 3.70 | Plasma glutathione peroxidase and its relationship to renal proximal tubule function. ( Avissar, N; Bhamre, S; Cohen, HJ; Ornt, DB; Salvatierra, O; Scandling, JD; Tham, DM; Tune, BM; Whitin, JC, 1998) |
| "Ifosfamide and cisplatin are active agents that are currently used in the treatment of osteosarcoma." | 3.70 | Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma. ( Arndt, C; Hawkins, D; Liedtke, R; Miser, J; Morgenstern, B; Wilson, D, 1999) |
| "We attempted to ascertain renal, hematologic, and neurologic tolerance to ifosfamide (IFX) in pediatric patients previously treated with large single and cumulative doses of cis-Diamminedichloroplatinum-II (CDP) for osteosarcoma (OS)." | 3.69 | Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations. ( Canpolat, C; Jaffe, N; Pearson, P; Robertson, R, 1996) |
| "A 20-year old man was treated for an osteosarcoma with a chemotherapy regimen that included ifosfamide, methotrexate, and doxorubicin." | 3.69 | Ifosfamide-induced Fanconi syndrome. ( Garcia, AA, 1995) |
| " A 16-year-old girl with metastatic osteosarcoma experienced recurrent bouts of symptomatic pancreatitis 24 hours after treatment with ifosfamide administered as a single agent." | 3.69 | Acute pancreatitis after ifosfamide therapy. ( Adamson, PC; Balis, FM; Blaney, SM; Izraeli, S, 1994) |
| "Neuroblastomas, nephroblastomas, malignant mesenchymal tumors, including rhabdomyosarcomas, Ewing's sarcomas, osteosarcomas, brain tumors, and non-Hodgkin's lymphomas respond to ifosfamide monotherapy." | 3.69 | Ifosfamide in the treatment of pediatric malignancies. ( Behrendt, H; de Kraker, J; Michiels, E; van den Berg, H; Voûte, PA, 1996) |
| "Patients with lung metastases originating from an osteosarcoma of the extremity received chemotherapy (high dose methotrexate, cisplatin, doxorubicin, and ifosfamide) followed by simultaneous resection of primary and metastatic lesions and additional chemotherapy." | 3.69 | Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. ( Bacci, G; Bertoni, F; Briccoli, A; Donati, D; Ferrari, S; Forni, C; Manfrini, M; Mercuri, M; Monti, C; Zanoni, A, 1997) |
| "Three chemotherapy regimens comprised of doxorubicin, high dose methotrexate, cisplatin, and ifosfamide were retrospectively analyzed in 67 pediatric osteosarcoma patients." | 3.69 | Neoadjuvant chemotherapy for pediatric osteosarcoma patients. ( Araki, N; Myoui, A; Shinto, Y; Uchida, A; Ueda, T; Yoshikawa, H, 1997) |
| "Eighteen patients with high grade malignant fibrous histiocytoma (MFH) of bone and 112 patients with high grade osteosarcoma (OS) of the extremity were treated with neoadjuvant chemotherapy comprised of methotrexate, cisplatinum, doxorubicin and ifosfamide." | 3.69 | Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen. ( Bacci, G; Bertoni, F; Campanacci, M; Cesari, M; Ferrari, S; Forni, C; Gasbarrini, A; Mercuri, M; Sottili, S; Tienghi, A, 1997) |
| "From January 1990 to December 1995 we treated 35 patients (pts) with bone and soft tissue sarcoma with ifosfamide (IFM)." | 3.69 | [The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T; Yonemoto, T, 1997) |
| "A total of 64 courses of ifosfamide (IFM) treatments for sarcoma patients were evaluated for toxic effects." | 3.68 | [Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas]. ( Ishii, T; Kitoh, M; Satoh, T; Tatezaki, S; Umeda, T, 1993) |
| "The relationship between the serum concentration of methotrexate and the prognosis has been studied in 108 patients with osteosarcoma of the extremities treated from September 1986 to December 1989 at the Chemotherapy Department of Rizzoli Hospital." | 3.68 | Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. ( Bacci, G; Battistini, A; Ferrari, S; Orlandi, M; Puggioli, C; Sassoli, V; Strazzari, S, 1993) |
| "To improve the accuracy of magnetic resonance imaging (MRI) in evaluating the response of osteosarcomas to preoperative chemotherapy, the authors developed a technique of mapping tumor necrosis and viability by quantitating slope values of gadolinium-DTPA (Gd-DTPA) uptake on dynamic fast low-angle shot (FLASH) images." | 3.68 | Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping. ( Fairclough, DL; Fletcher, BD; Hanna, SL; Le, AH; Meyer, WH; Parham, DM, 1992) |
| "A 13-year-old boy with unresectable pulmonary metastatic osteosarcoma, which was refractory to high dose methotrexate, adriamycin, cisplatin and combination of bleomycin, cyclophosphamide and actinomycin D, was treated by aggressive chemotherapy including the combination of ifosfamide (1 g/m2 x day 1-4), Carboplatin (100 mg/m2 x day 1-4) and Vindesine (4 mg/m2 x day 1)." | 3.68 | [Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report]. ( Fujita, H; Ishimoto, K; Kiyokawa, N; Kyo, K; Mizuno, T; Takada, K; Yabuta, K, 1991) |
| "In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1." | 3.67 | High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985) |
| "The biologic activity in terms of survival of normal hematopoietic stem, osteosarcoma, and L1210 leukemia cells was determined for the following compounds:cyclophosphamide, its derivatives isophosphamide and trophosphamide, its possible metabolites nor-nitrogen mustard, hydroxylamine mustard, 4-ketocyclophosphamide, and and acrolein, and two substitutes for its primary active metabolite 4-hydroxycyclosphamide anhydro-dimer (4-hydroxy-CP-anhydro-dimer) and 4-hydroperoxycyclophosphamide (4-hydroperoxy-CP)." | 3.65 | Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271). ( Lelieveld, P; van Putten, LM, 1976) |
| "Based on preclinical data for the antitumour effect of zoledronate in osteosarcoma, we assessed whether zoledronate combined with chemotherapy and surgery improved event-free survival in children and adults with osteosarcoma." | 2.82 | Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. ( Blay, JY; Bompas, E; Bonnet, N; Brisse, H; Brugières, L; Chevance, A; Corradini, N; Entz-Werlé, N; Gentet, JC; Gomez-Brouchet, A; Gouin, F; Guinebretière, JM; Italiano, A; Le Deley, MC; Lervat, C; Marec-Bérard, P; Mascard, E; Pacquement, H; Penel, N; Petit, P; Piperno-Neumann, S; Rédini, F; Tabone, MD, 2016) |
| "The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue." | 2.76 | Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ( Billups, CA; Daw, NC; Jenkins, JJ; Luchtman-Jones, L; Neel, MD; Quintana, J; Rao, BN; Santana, VM; Villarroel, M; Wu, J, 2011) |
| " The authors evaluated the impact of factors such as age and prior nephrotoxic agents on MTX pharmacokinetics in children and young adults with osteosarcoma and examined whether MTX pharmacokinetic parameters were associated with outcome." | 2.71 | High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. ( Crews, KR; Daw, NC; Link, MP; Liu, T; Meyer, WH; Panetta, JC; Rodriguez-Galindo, C; Tan, M, 2004) |
| " was applied in combination with high-dose methotrexate (HDMTX) and adriamycin (ADM) within a three-drug regimen." | 2.70 | A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. ( Bacchini, P; Bacci, G; Bertoni, F; De Giorgi, U; Ferrari, S; Fiorentini, G; Forni, C; Longhi, A; Mercuri, M; Picci, P; Rimondini, S; Tienghi, A, 2001) |
| "Malignant fibrous histiocytoma (MFH) is a rare bone tumor usually treated like osteosarcoma." | 2.68 | Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors. ( Bacci, G; Ferrari, S; Mercuri, M; Picci, P, 1997) |
| "Radiation-induced osteosarcomas are a recognized complication of radiation therapy." | 2.53 | Radiation-induced osteosarcoma of the skull base after radiation therapy in a patient with nasopharyngeal carcinoma: a case report and review of the literature. ( Benjaafar, N; Echchikhi, Y; Kebdani, T; Loughlimi, H; Touil, A, 2016) |
| "Ifosfamide has been used in neoadjuvant chemotherapy since the mid-1980s." | 2.52 | Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials. ( Lai, Z; Lin, Y; Mo, Y; Su, W; Wu, F; Wu, J; Yang, Z, 2015) |
| "Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration." | 2.52 | An update on chemotherapy for osteosarcoma. ( Ferrari, S; Serra, M, 2015) |
| "Primary malignant cardiac tumors are very rare." | 2.50 | Recurrent primary cardiac osteosarcoma: a case report and literature review. ( Asadi, N; Bini, A; Caroli, G; Dell'Amore, A; Dolci, G; Stella, F, 2014) |
| "Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in eradicating primary tumor and pulmonary metastases in the mid-twentieth century." | 2.50 | Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. ( Jaffe, N, 2014) |
| "Osteosarcoma is a clinically heterogeneous disease which continues to resist biologic diagnosis, classification, or staging." | 2.39 | Problems and controversies in the management of childhood sarcomas. ( Womer, RB, 1996) |
| "Osteosarcoma is one of the most common childhood bone malignancies." | 1.91 | Outcomes and survival rates of childhood osteosarcoma in Iran, A report from MAHAK Pediatric Cancer Treatment and Research Center, from 2007 to 2020. ( Mehrvar, A; Mehrvar, N; Sadeghi, Y; Tashvighi, M, 2023) |
| "However, because sarcoma is very rare, there is little evidence regarding the management of elderly patients with sarcoma." | 1.72 | Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. ( Ozaki, T; Tanaka, K, 2022) |
| "Most aspects of osteosarcoma have been addressed in detail, but there is no comprehensive analysis of deceased patients and causes of death." | 1.72 | Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS). ( Bielack, SS; Blattmann, C; Borkhardt, A; Csóka, M; Hassenpflug, W; Hecker-Nolting, S; Kabíčková, E; Kager, L; Kessler, T; Kevric, M; Kratz, C; Kühne, T; Lehrnbecher, T; Mayer-Steinacker, R; Mettmann, V; Metzler, M; Reichardt, P; Rossig, C; Sorg, B; von Luettichau, I; Windhager, R, 2022) |
| "Osteosarcoma is the most common primary bone malignancy in both children and adults." | 1.62 | A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma. ( Bui, NQ; Charville, GW; Ganjoo, KN; Hu, BD; Pribnow, A; Saadeh, NL; Spunt, SL; Testa, S, 2021) |
| "Osteosarcoma is the most common primary malignant bone tumor, and its standard treatment is a combination of surgery and chemotherapy." | 1.62 | The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma. ( Abe, K; Araki, Y; Asano, Y; Hayashi, K; Higuchi, T; Igarashi, K; Ikeda, H; Miwa, S; Morinaga, S; Nojima, T; Takeuchi, A; Taniguchi, Y; Tsuchiya, H; Yamamoto, N; Yonezawa, H, 2021) |
| "The management of osteosarcoma is challenging especially in lower-income and middle-income countries, and there is an unmet need to evolve efficient and sustainable chemotherapy regimens." | 1.51 | Osteosarcoma journey over two decades in India: Small steps, big changes. ( Bajpai, J; Banavali, S; Chandrasekharan, A; Ghosh, J; Gupta, S; Hingmare, S; Mandal, T; Rangarajan, B; Rekhi, B; Shah, K; Shetty, N; Simha, V; Vora, T, 2019) |
| "Ifosfamide (IFA) is a potent alkylating antitumoral agent, but its use is limited by neurological side effects." | 1.48 | Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases. ( Bellien, J; Duflot, T; Filhon, B; Joannidès, R; Lamoureux, F; Marie-Cardine, A; Massy-Guillemant, N; Pereira, T; Verstuyft, C, 2018) |
| "Considering the physical condition of patient, the patient underwent surgical resection of the right lung lesion after receiving endostar combined with chemotherapy and maintained endostar alone for 47 cycles." | 1.46 | Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( Dong, Y; Jiang, S; Wang, G, 2017) |
| "Ifosfamid-related encephalopathy (IRE) is a rare but severe adverse event, without clearly identified risk factors." | 1.46 | [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients]. ( Defachelles, AS; Deplanque, D; Lervat, C; Marliot, G; Penel, N; Peugniez, C; Ryckewaert, T; Sakji, I; Stern, N, 2017) |
| "Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment." | 1.42 | Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas? ( Fan, Z; Guadagnolo, BA; Lewis, VO; Lin, PP; Patel, S, 2015) |
| "Information is scarce on systemic treatment of pelvic osteosarcoma because most chemotherapy protocols for osteosarcoma include patients with extremity tumors and aged up to 30-40 years." | 1.38 | Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years. ( Alberghini, M; Fabbri, N; Ferrari, C; Ferrari, S; Palmerini, E; Picci, P; Staals, E, 2012) |
| "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments." | 1.37 | Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011) |
| "He was initially diagnosed with a pulmonary thromboembolism." | 1.37 | Metastatic osteosarcoma presenting as a single pulmonary microembolus. ( Chin, C; Midulla, P; Shapiro, M; Wistinghausen, B, 2011) |
| "Ifosfamide is a widely used chemotherapeutic agent for the treatment of a broad spectrum of solid tumors." | 1.36 | Ifosfamide-induced encephalopathy and movement disorder. ( Ames, B; Chaffee, S; Kim, J; Lewis, LD; Morse, R, 2010) |
| "The effect of immunotherapy with interleukin-18 (IL-18) in combination with preoperative chemotherapy on the postoperative progression of pulmonary metastasis was examined using a spontaneous pulmonary metastasis model of mouse osteosarcoma." | 1.35 | Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. ( Futani, H; Hata, M; Kogoe, N; Nakasho, K; Ohyama, H; Okamura, H; Terada, N; Yamada, N; Yamanegi, K, 2009) |
| "Osteosarcomas are highly malignant tumours of bone, and are rare in the craniofacial area." | 1.35 | Interdisciplinary combined treatment of craniofacial osteosarcoma with neoadjuvant and adjuvant chemotherapy and excision of the tumour: a retrospective study. ( Bacon, C; Egerer, G; Freier, K; Hofele, CM; Thiele, OC, 2008) |
| "The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma." | 1.32 | Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. ( Bielack, SS; Branscheid, D; Flege, S; Gadner, H; Jundt, G; Jürgens, H; Kabisch, H; Kager, L; Kastner, U; Kempf-Bielack, B; Kotz, R; Pötschger, U; Reichardt, P; Salzer-Kuntschik, M; Winkelmann, W; Zoubek, A, 2003) |
| "Osteosarcoma is the most common primary malignant tumor of bone (annual incidence: 2 - 3/Mio)." | 1.32 | [Goal and results of the COSS study]. ( Bielack, S; Flege, S, 2004) |
| "Osteosarcoma is a primary malignancy of bone." | 1.31 | Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. ( Berend, KR; Dibernardo, L; Harrelson, JM; Moore, JO; Pietrobon, R; Scully, SP, 2001) |
| "The OHS osteosarcoma tumors caused sclerotic lesions with high and uniform isotope uptake, and the MHMX unclassified sarcoma showed a mixed pattern with both sclerotic and lytic areas, whereas the LOX melanoma caused lytic bone lesions with low uptake of the radionuclide." | 1.29 | Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats. ( Bruland, O; Fodstad, O; Kjønniksen, I; Winderen, M, 1994) |
| "Therapy for osteosarcoma has changed considerably over the last two decades." | 1.29 | [Chemotherapy for osteosarcoma--trends in recent years]. ( Fujinami, S; Nakaseko, K; Ogihara, Y, 1993) |
| "Ifosfamide was given to 61 patients with malignant solid tumors diagnosed before the age of 21 years." | 1.27 | Phase II trial of ifosfamide in children with malignant solid tumors. ( Douglass, EC; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (3.83) | 18.7374 |
| 1990's | 70 (26.82) | 18.2507 |
| 2000's | 80 (30.65) | 29.6817 |
| 2010's | 83 (31.80) | 24.3611 |
| 2020's | 18 (6.90) | 2.80 |
| Authors | Studies |
|---|---|
| Testa, S | 1 |
| Hu, BD | 1 |
| Saadeh, NL | 1 |
| Pribnow, A | 1 |
| Spunt, SL | 2 |
| Charville, GW | 1 |
| Bui, NQ | 1 |
| Ganjoo, KN | 1 |
| Tanaka, K | 2 |
| Ozaki, T | 2 |
| Stacchiotti, S | 1 |
| Van der Graaf, WTA | 1 |
| Sanfilippo, RG | 1 |
| Marreaud, SI | 1 |
| Van Houdt, WJ | 1 |
| Judson, IR | 1 |
| Gronchi, A | 1 |
| Gelderblom, H | 3 |
| Litiere, S | 1 |
| Kasper, B | 1 |
| Luminais, SN | 1 |
| Chen, XT | 1 |
| Roman, D | 1 |
| Ma, B | 1 |
| Christ, AB | 1 |
| Hu, JS | 1 |
| Bielack, SS | 7 |
| Blattmann, C | 1 |
| Borkhardt, A | 1 |
| Csóka, M | 1 |
| Hassenpflug, W | 1 |
| Kabíčková, E | 1 |
| Kager, L | 3 |
| Kessler, T | 1 |
| Kratz, C | 1 |
| Kühne, T | 2 |
| Kevric, M | 2 |
| Lehrnbecher, T | 1 |
| Mayer-Steinacker, R | 2 |
| Mettmann, V | 1 |
| Metzler, M | 1 |
| Reichardt, P | 2 |
| Rossig, C | 1 |
| Sorg, B | 1 |
| von Luettichau, I | 1 |
| Windhager, R | 1 |
| Hecker-Nolting, S | 1 |
| Long, Z | 1 |
| Lu, Y | 1 |
| Li, M | 1 |
| Ji, C | 1 |
| Chen, G | 1 |
| Li, J | 2 |
| Xiang, L | 1 |
| Yu, H | 1 |
| Wang, Q | 2 |
| Wang, Z | 4 |
| Mehrvar, A | 1 |
| Mehrvar, N | 1 |
| Sadeghi, Y | 1 |
| Tashvighi, M | 1 |
| Foroughi, A | 1 |
| Arefpour, AM | 1 |
| Nikoofar, A | 1 |
| Sanei, M | 1 |
| Mahdavi, SH | 1 |
| Javadinia, SA | 1 |
| Zhang, B | 1 |
| Zhang, Y | 2 |
| Li, R | 1 |
| Lu, X | 1 |
| Han, J | 1 |
| Yu, Y | 1 |
| Wu, S | 1 |
| Zhang, W | 2 |
| Zhao, M | 1 |
| Yao, Y | 7 |
| Hu, Y | 1 |
| Wang, W | 3 |
| Liu, X | 1 |
| Yu, W | 4 |
| Cheng, J | 1 |
| Yu, L | 1 |
| Bao, Q | 1 |
| Zhang, G | 1 |
| Yu, X | 2 |
| Song, R | 1 |
| Verma, P | 1 |
| Jain, S | 1 |
| Kapoor, G | 1 |
| Tripathi, R | 1 |
| Sharma, P | 1 |
| Doval, DC | 1 |
| Sarbay, H | 1 |
| Demir, ÜF | 1 |
| Yılmaz, G | 1 |
| Atay, AA | 1 |
| Malbora, B | 1 |
| Yahiro, K | 1 |
| Matsumoto, Y | 1 |
| Araki, Y | 2 |
| Yamamoto, N | 1 |
| Hayashi, K | 1 |
| Takeuchi, A | 1 |
| Miwa, S | 1 |
| Igarashi, K | 1 |
| Higuchi, T | 1 |
| Abe, K | 1 |
| Taniguchi, Y | 1 |
| Yonezawa, H | 1 |
| Morinaga, S | 1 |
| Asano, Y | 1 |
| Ikeda, H | 1 |
| Nojima, T | 1 |
| Tsuchiya, H | 2 |
| Paul, A | 1 |
| Duncan, A | 1 |
| Bacchetta, J | 1 |
| Dubourg, L | 2 |
| Marec-Bérard, P | 4 |
| Tanné, C | 1 |
| Hiraga, H | 1 |
| Gaspar, N | 2 |
| Campbell-Hewson, Q | 1 |
| Huang, J | 1 |
| Okpara, CE | 1 |
| Bautista, F | 1 |
| Kim, SH | 2 |
| Shin, KH | 3 |
| Moon, SH | 1 |
| Kong, Y | 1 |
| Suh, JS | 2 |
| Yang, WI | 2 |
| Deng, ZP | 1 |
| Liu, BY | 1 |
| Sun, Y | 4 |
| Jin, T | 1 |
| Li, B | 2 |
| Ding, Y | 1 |
| Niu, XH | 1 |
| Bajpai, J | 2 |
| Chandrasekharan, A | 2 |
| Talreja, V | 1 |
| Simha, V | 2 |
| Chandrakanth, MV | 1 |
| Rekhi, B | 2 |
| Khurana, S | 1 |
| Khan, A | 1 |
| Vora, T | 2 |
| Ghosh, J | 2 |
| Banavali, SD | 1 |
| Gupta, S | 2 |
| Meazza, C | 1 |
| Cefalo, G | 2 |
| Massimino, M | 1 |
| Daolio, P | 1 |
| Pastorino, U | 1 |
| Scanagatta, P | 1 |
| Morosi, C | 1 |
| Podda, M | 1 |
| Ferrari, A | 1 |
| Terenziani, M | 1 |
| Spreafico, F | 1 |
| Casanova, M | 1 |
| Parafioriti, A | 2 |
| Collini, P | 1 |
| Gandola, L | 1 |
| Bastoni, S | 1 |
| Biassoni, V | 1 |
| Schiavello, E | 1 |
| Chiaravalli, S | 1 |
| Puma, N | 1 |
| Bergamaschi, L | 1 |
| Luksch, R | 1 |
| Occean, BV | 2 |
| Pacquement, H | 5 |
| Bompas, E | 3 |
| Bouvier, C | 1 |
| Brisse, HJ | 1 |
| Castex, MP | 1 |
| Cheurfa, N | 1 |
| Corradini, N | 3 |
| Delaye, J | 2 |
| Entz-Werlé, N | 3 |
| Gentet, JC | 6 |
| Italiano, A | 3 |
| Lervat, C | 3 |
| Mascard, E | 2 |
| Redini, F | 3 |
| Saumet, L | 1 |
| Schmitt, C | 4 |
| Tabone, MD | 4 |
| Verite-Goulard, C | 1 |
| Le Deley, MC | 5 |
| Piperno-Neumann, S | 3 |
| Brugieres, L | 5 |
| Duflot, T | 1 |
| Marie-Cardine, A | 1 |
| Verstuyft, C | 1 |
| Filhon, B | 1 |
| Pereira, T | 1 |
| Massy-Guillemant, N | 1 |
| Joannidès, R | 1 |
| Bellien, J | 1 |
| Lamoureux, F | 1 |
| Jiang, S | 1 |
| Wang, G | 1 |
| Dong, Y | 2 |
| Savani, M | 1 |
| Skubitz, KM | 1 |
| Zhang, SP | 1 |
| Li, X | 1 |
| Li, H | 2 |
| Sun, XH | 1 |
| Yan, XF | 1 |
| Wakamatsu, T | 1 |
| Kakunaga, S | 1 |
| Takenaka, S | 1 |
| Outani, H | 1 |
| Hamada, K | 2 |
| Imura, Y | 1 |
| Hori, Y | 1 |
| Naka, N | 3 |
| Kudawara, I | 3 |
| Yoshikawa, H | 5 |
| Ueda, T | 4 |
| Mandal, T | 1 |
| Shah, K | 1 |
| Hingmare, S | 1 |
| Rangarajan, B | 1 |
| Shetty, N | 1 |
| Banavali, S | 1 |
| Ray-Coquard, I | 2 |
| Laurence, V | 1 |
| Cupissol, D | 1 |
| Perrin, C | 1 |
| Penel, N | 3 |
| Rios, M | 1 |
| Le Cesne, A | 1 |
| Anract, P | 1 |
| de Pinieux, G | 1 |
| Collard, O | 1 |
| Bertucci, F | 1 |
| Duffaud, F | 1 |
| Blay, JY | 4 |
| Aoki, Y | 1 |
| Araki, N | 3 |
| Nakanishi, H | 1 |
| Matsumine, A | 2 |
| Ieguchi, M | 2 |
| Mori, S | 1 |
| Myoui, A | 4 |
| Kuratsu, S | 1 |
| Hashimoto, N | 2 |
| Urakawa, H | 1 |
| Tsukushi, S | 1 |
| Tsurudome, I | 1 |
| Hirata, A | 1 |
| Arai, E | 1 |
| Kozawa, E | 1 |
| Futamura, N | 1 |
| Miyahara, R | 1 |
| Ishiguro, N | 1 |
| Nishida, Y | 1 |
| Dell'Amore, A | 1 |
| Asadi, N | 1 |
| Caroli, G | 1 |
| Dolci, G | 1 |
| Bini, A | 1 |
| Stella, F | 1 |
| Bi, W | 1 |
| Han, G | 2 |
| Jia, J | 1 |
| Xu, M | 2 |
| Choeyprasert, W | 2 |
| Natesirinilkul, R | 1 |
| Charoenkwan, P | 1 |
| Sittipreechacharn, S | 1 |
| Kobys, VL | 1 |
| Konovalenko, VF | 1 |
| Repinа, NV | 1 |
| Golovko, TS | 1 |
| Gulak, LO | 1 |
| Tarasova, TO | 1 |
| Zaharycheva, EV | 1 |
| Matyushok, OF | 1 |
| Nishimura, H | 1 |
| Enokida, H | 1 |
| Nagano, S | 1 |
| Yokouchi, M | 1 |
| Hayami, H | 1 |
| Komiya, S | 1 |
| Nakagawa, M | 1 |
| Boye, K | 1 |
| Del Prever, AB | 3 |
| Eriksson, M | 2 |
| Saeter, G | 3 |
| Tienghi, A | 5 |
| Lindholm, P | 1 |
| Fagioli, F | 4 |
| Skjeldal, S | 1 |
| Ferrari, S | 33 |
| Hall, KS | 3 |
| Robert, G | 1 |
| Chappé, C | 1 |
| Taque, S | 1 |
| Bruneau, B | 1 |
| Gandemer, V | 1 |
| Sio, TT | 1 |
| Vu, CC | 1 |
| Sohawon, S | 1 |
| Van Houtte, P | 1 |
| Thariat, J | 1 |
| Novotny, PJ | 1 |
| Miller, RC | 1 |
| Bar-Sela, G | 1 |
| Sun, L | 1 |
| Li, Y | 1 |
| Zhang, J | 1 |
| Ye, Z | 1 |
| Kenney, LB | 1 |
| Duffey-Lind, E | 1 |
| Ebb, D | 1 |
| Sklar, CA | 1 |
| Grier, H | 2 |
| Diller, L | 1 |
| Kushnir, I | 1 |
| Kolander, Y | 1 |
| Bickels, J | 2 |
| Gortzak, Y | 1 |
| Flusser, G | 1 |
| Issakov, J | 2 |
| Merimsky, O | 2 |
| Jaffe, N | 5 |
| Necessary, CA | 1 |
| Roffwarg, D | 1 |
| Ellis, D | 1 |
| Seok, SO | 1 |
| Cho, YJ | 1 |
| Noh, JK | 1 |
| Hung, GY | 2 |
| Yen, HJ | 1 |
| Yen, CC | 1 |
| Chen, WM | 1 |
| Chen, PC | 1 |
| Wu, HT | 1 |
| Chiou, HJ | 1 |
| Chang, WH | 1 |
| Hsu, HE | 1 |
| Xu, S | 1 |
| Xiao, X | 1 |
| Whelan, JS | 4 |
| Marina, N | 2 |
| Smeland, S | 4 |
| Jovic, G | 1 |
| Hook, JM | 1 |
| Krailo, M | 2 |
| Anninga, J | 1 |
| Butterfass-Bahloul, T | 1 |
| Böhling, T | 2 |
| Calaminus, G | 1 |
| Capra, M | 1 |
| Deffenbaugh, C | 1 |
| Dhooge, C | 1 |
| Flanagan, AM | 1 |
| Goorin, A | 1 |
| Gorlick, R | 2 |
| Gosheger, G | 2 |
| Grimer, RJ | 1 |
| Helmke, K | 1 |
| Hogendoorn, PC | 3 |
| Jundt, G | 2 |
| Kuehne, T | 1 |
| Lau, CC | 1 |
| Letson, GD | 1 |
| Meyer, J | 1 |
| Meyers, PA | 5 |
| Morris, C | 1 |
| Mottl, H | 1 |
| Nadel, H | 3 |
| Nagarajan, R | 1 |
| Randall, RL | 1 |
| Schomberg, P | 1 |
| Schwarz, R | 1 |
| Teot, LA | 2 |
| Sydes, MR | 1 |
| Bernstein, M | 2 |
| Tang, L | 2 |
| Lin, F | 4 |
| Shen, Z | 5 |
| Vredenburg, G | 1 |
| den Braver-Sewradj, S | 1 |
| van Vugt-Lussenburg, BM | 1 |
| Vermeulen, NP | 1 |
| Commandeur, JN | 1 |
| Vos, JC | 1 |
| Li, YY | 1 |
| Jiang, XM | 1 |
| Dong, YG | 1 |
| Xu, G | 1 |
| Ma, YB | 1 |
| Pakakasama, S | 1 |
| Sirachainan, N | 1 |
| Songdej, D | 1 |
| Chuansumrit, A | 1 |
| Anurathapan, U | 1 |
| Hongeng, S | 1 |
| Nartthanarung, A | 1 |
| Su, W | 1 |
| Lai, Z | 1 |
| Wu, F | 1 |
| Lin, Y | 1 |
| Mo, Y | 1 |
| Yang, Z | 1 |
| Wu, J | 2 |
| Hattinger, CM | 2 |
| Michelacci, F | 1 |
| Sella, F | 1 |
| Magagnoli, G | 1 |
| Benini, S | 2 |
| Gambarotti, M | 1 |
| Palmerini, E | 6 |
| Picci, P | 17 |
| Serra, M | 5 |
| Nakata, H | 1 |
| Miyazaki, T | 1 |
| Iwasaki, T | 1 |
| Nakamura, A | 1 |
| Kidani, T | 1 |
| Sakayama, K | 1 |
| Masumoto, J | 1 |
| Miura, H | 1 |
| Huang, YJ | 1 |
| He, AN | 1 |
| Sun, YJ | 1 |
| Min, DL | 1 |
| Fan, Z | 1 |
| Patel, S | 1 |
| Lewis, VO | 2 |
| Guadagnolo, BA | 1 |
| Lin, PP | 2 |
| Shkalim-Zemer, V | 1 |
| Ash, S | 1 |
| Toledano, H | 1 |
| Kollender, Y | 2 |
| Yaniv, I | 1 |
| Cohen, IJ | 2 |
| Nataraj, V | 1 |
| Batra, A | 1 |
| Rastogi, S | 1 |
| Khan, SA | 1 |
| Sharma, MC | 1 |
| Vishnubhatla, S | 1 |
| Bakhshi, S | 1 |
| Schwartz, CL | 4 |
| Wexler, LH | 1 |
| Krailo, MD | 2 |
| Devidas, M | 2 |
| Steinherz, LJ | 1 |
| Goorin, AM | 7 |
| Gebhardt, MC | 3 |
| Healey, JH | 2 |
| Sato, JK | 1 |
| Grier, HE | 4 |
| Bernstein, ML | 3 |
| Lipshultz, SE | 1 |
| Chen, B | 1 |
| Yang, JZ | 1 |
| Wang, LF | 1 |
| Zhang, YJ | 1 |
| Lin, XJ | 1 |
| Fan, XL | 1 |
| Cai, GP | 1 |
| Zhu, LL | 1 |
| Ding, GM | 1 |
| Yonemoto, T | 2 |
| Takahashi, M | 1 |
| Maru, M | 1 |
| Tomioka, A | 1 |
| Saito, M | 1 |
| Tazaki, M | 1 |
| Tsuchiya, M | 1 |
| Iwata, S | 1 |
| Kamoda, H | 1 |
| Ishii, T | 3 |
| Yılmaz, S | 1 |
| Özçakar, ZB | 1 |
| Taktak, A | 1 |
| Kiremitçi, S | 1 |
| Ensari, A | 1 |
| Dinçaslan, H | 1 |
| Yalçınkaya, F | 1 |
| Petit, P | 1 |
| Brisse, H | 1 |
| Gomez-Brouchet, A | 1 |
| Guinebretière, JM | 2 |
| Gouin, F | 2 |
| Chevance, A | 1 |
| Bonnet, N | 1 |
| Biason, P | 1 |
| Iacoboni, E | 1 |
| Gagno, S | 1 |
| Fanelli, M | 1 |
| Tavanti, E | 1 |
| Vella, S | 1 |
| Roli, A | 1 |
| Roncato, R | 1 |
| Giodini, L | 1 |
| Scotlandi, K | 2 |
| Toffoli, G | 1 |
| Echchikhi, Y | 1 |
| Loughlimi, H | 1 |
| Touil, A | 1 |
| Kebdani, T | 1 |
| Benjaafar, N | 1 |
| Yodoya, N | 1 |
| Iwamoto, S | 1 |
| Azuma, E | 1 |
| Toyoda, H | 1 |
| Miura, Y | 1 |
| Nakatani, K | 1 |
| Imai, H | 1 |
| Hirayama, M | 1 |
| Komada, Y | 1 |
| Stern, N | 1 |
| Sakji, I | 1 |
| Defachelles, AS | 2 |
| Ryckewaert, T | 1 |
| Marliot, G | 1 |
| Peugniez, C | 1 |
| Deplanque, D | 1 |
| Helman, LJ | 1 |
| Reaman, GH | 1 |
| Ottaviani, S | 1 |
| Forest, A | 1 |
| Descamps, V | 1 |
| Meyer, O | 1 |
| Dieudé, P | 1 |
| Cozza, R | 1 |
| Devito, R | 1 |
| De Ioris, MA | 1 |
| Zama, M | 1 |
| Boldrini, R | 1 |
| Fidani, P | 1 |
| Donfrancesco, A | 1 |
| Tomita, Y | 1 |
| Inoue, A | 1 |
| Fujimoto, T | 2 |
| Hatazawa, J | 1 |
| Hingorani, P | 1 |
| Piperdi, S | 1 |
| Pressman, L | 1 |
| Lin, J | 1 |
| Kolb, EA | 1 |
| Staals, E | 2 |
| Abate, ME | 1 |
| Longhi, A | 14 |
| Cesari, M | 6 |
| Balladelli, A | 3 |
| Pratelli, L | 1 |
| Bacci, G | 29 |
| Zoccali, C | 1 |
| Prencipe, U | 1 |
| Ferraresi, V | 1 |
| Salducca, N | 1 |
| Lashkari, A | 1 |
| Chow, WA | 1 |
| Valdes, F | 1 |
| Leong, L | 1 |
| Phan, V | 1 |
| Twardowski, P | 1 |
| Kapoor, N | 1 |
| Molina, A | 1 |
| Al-Kadhimi, Z | 1 |
| Frankel, P | 1 |
| Somlo, G | 1 |
| Peeters, J | 1 |
| Meitert, J | 1 |
| Paulides, M | 1 |
| Beck, JD | 1 |
| Langer, T | 1 |
| Yamada, N | 1 |
| Hata, M | 1 |
| Ohyama, H | 1 |
| Yamanegi, K | 1 |
| Kogoe, N | 1 |
| Nakasho, K | 1 |
| Futani, H | 2 |
| Okamura, H | 1 |
| Terada, N | 2 |
| Oberlin, O | 1 |
| Fawaz, O | 1 |
| Rey, A | 1 |
| Niaudet, P | 1 |
| Ridola, V | 1 |
| Orbach, D | 1 |
| Bergeron, C | 1 |
| Rubie, H | 1 |
| Munzer, M | 1 |
| Plantaz, D | 1 |
| Deville, A | 1 |
| Minard, V | 1 |
| Leverger, G | 1 |
| de Vathaire, F | 1 |
| Bruheim, S | 1 |
| Xi, Y | 1 |
| Ju, J | 1 |
| Fodstad, O | 2 |
| Ames, B | 1 |
| Lewis, LD | 1 |
| Chaffee, S | 1 |
| Kim, J | 1 |
| Morse, R | 1 |
| Janeway, KA | 1 |
| Zhao, H | 2 |
| Chen, P | 1 |
| Machak, GN | 1 |
| Polotskiĭ, BE | 1 |
| Meluzova, OM | 1 |
| Chernov, IS | 1 |
| Aliev, MD | 1 |
| Buchbinder, D | 1 |
| Steinberg, G | 1 |
| Linetsky, M | 1 |
| Casillas, J | 1 |
| Gougelet, A | 1 |
| Pissaloux, D | 1 |
| Besse, A | 1 |
| Perez, J | 1 |
| Duc, A | 1 |
| Dutour, A | 1 |
| Alberti, L | 1 |
| Ambroszkiewicz, J | 1 |
| Gajewska, J | 1 |
| Klepacka, T | 1 |
| Chełchowska, M | 1 |
| Laskowska-Klita, T | 1 |
| Woźniak, W | 1 |
| Wang, Y | 1 |
| Bi, WZ | 1 |
| Wang, DJ | 1 |
| Lu, SB | 1 |
| Zhang, L | 1 |
| Zhao, B | 1 |
| Shapiro, M | 1 |
| Wistinghausen, B | 1 |
| Midulla, P | 1 |
| Chin, C | 1 |
| Cui, Q | 1 |
| Jiang, W | 1 |
| Guo, J | 1 |
| Liu, C | 1 |
| Li, D | 1 |
| Wang, X | 1 |
| Zeng, Y | 1 |
| Bruland, OS | 1 |
| Hjorth, L | 1 |
| Brosjö, O | 2 |
| Bjerkehagen, B | 1 |
| Osterlundh, G | 1 |
| Jakobson, A | 1 |
| Monge, OR | 1 |
| Björk, O | 1 |
| Alvegaard, TA | 1 |
| Daw, NC | 4 |
| Neel, MD | 2 |
| Rao, BN | 4 |
| Billups, CA | 2 |
| Jenkins, JJ | 4 |
| Quintana, J | 1 |
| Luchtman-Jones, L | 1 |
| Villarroel, M | 1 |
| Santana, VM | 2 |
| Hong, S | 1 |
| Shin, SJ | 1 |
| Jung, M | 1 |
| Jeong, J | 1 |
| Lee, YJ | 1 |
| Roh, JK | 1 |
| Rha, SY | 1 |
| Anninga, JK | 1 |
| Fiocco, M | 1 |
| Kroep, JR | 1 |
| Taminiau, AH | 1 |
| Egeler, RM | 1 |
| Zheng, S | 2 |
| Fernandez-Pineda, I | 1 |
| Bahrami, A | 1 |
| Green, JF | 1 |
| McGregor, LM | 1 |
| Davidoff, AM | 1 |
| Sandoval, JA | 1 |
| Zils, K | 1 |
| Ebner, F | 1 |
| Ott, M | 1 |
| Müller, J | 1 |
| Baumhoer, D | 1 |
| Greulich, M | 1 |
| Rehnitz, D | 1 |
| Rempen, A | 1 |
| Schaetzle, S | 1 |
| Wilhelm, M | 1 |
| Bielack, S | 5 |
| Fukunaga, S | 1 |
| Tsukamoto, Y | 1 |
| Ono, J | 1 |
| Okamoto, N | 1 |
| Otsuka, Y | 1 |
| Tanizawa, T | 1 |
| Tomatsuri, M | 1 |
| Yoshiya, S | 1 |
| He, A | 1 |
| Qi, W | 1 |
| Huang, Y | 1 |
| Yang, Y | 2 |
| Ruggieri, P | 5 |
| Tamburini, A | 1 |
| Capanna, R | 4 |
| Comandone, A | 4 |
| Bertulli, R | 1 |
| Bisogno, G | 2 |
| Alberghini, M | 2 |
| Linari, A | 1 |
| Maki, RG | 1 |
| Iwamoto, Y | 1 |
| Punanov, IuA | 1 |
| Gafton, GI | 1 |
| Gudz', IuV | 1 |
| Nabokov, VV | 1 |
| Ivanova, TV | 1 |
| Safonova, SA | 1 |
| Levchenko, EV | 1 |
| Kupatadze, DD | 1 |
| Novik, VI | 1 |
| Lazareva, IuR | 1 |
| Krzhivitskiĭ, PI | 1 |
| Petrov, VG | 1 |
| Yamada, SM | 1 |
| Ishii, Y | 1 |
| Yamada, S | 1 |
| Kuribayashi, S | 1 |
| Kumita, S | 1 |
| Matsuno, A | 1 |
| Min, D | 1 |
| Tan, L | 1 |
| Batschinski, K | 1 |
| Dervisis, NG | 1 |
| Kitchell, BE | 1 |
| Fabbri, N | 7 |
| Ferrari, C | 1 |
| Patel, SJ | 1 |
| Lynch, JW | 1 |
| Johnson, T | 1 |
| Carroll, RR | 1 |
| Schumacher, C | 1 |
| Spanier, S | 1 |
| Scarborough, M | 1 |
| Janinis, J | 1 |
| McTiernan, A | 2 |
| Driver, D | 1 |
| Mitchell, C | 1 |
| Cassoni, AM | 1 |
| Pringle, J | 2 |
| Kilby, A | 1 |
| Wodowski, K | 1 |
| Hill, DA | 1 |
| Pappo, AS | 2 |
| Shochat, SJ | 3 |
| Kun, LE | 1 |
| Reverter-Branchat, G | 1 |
| Manara, MC | 1 |
| Incaprera, M | 1 |
| Bertoni, F | 13 |
| Mercuri, M | 14 |
| Briccoli, A | 8 |
| Macchiagodena, M | 1 |
| Vitali, G | 1 |
| Zoubek, A | 2 |
| Pötschger, U | 1 |
| Kastner, U | 1 |
| Flege, S | 2 |
| Kempf-Bielack, B | 1 |
| Branscheid, D | 1 |
| Kotz, R | 6 |
| Salzer-Kuntschik, M | 6 |
| Winkelmann, W | 1 |
| Kabisch, H | 1 |
| Jürgens, H | 7 |
| Gadner, H | 2 |
| Rocca, M | 1 |
| Donati, D | 5 |
| Bacchini, P | 3 |
| Giacomini, S | 1 |
| Forni, C | 14 |
| Manfrini, M | 4 |
| Galletti, S | 2 |
| Loro, L | 2 |
| Mazzei, T | 2 |
| Beghelli, C | 2 |
| Biolchini, A | 2 |
| Tremosini, M | 2 |
| Triggiani, A | 1 |
| Carli, M | 1 |
| Passone, E | 1 |
| Perilongo, G | 1 |
| De Paolis, M | 1 |
| Setola, E | 1 |
| Inbar, M | 1 |
| Meller, I | 2 |
| Palmert, MR | 1 |
| Alexander, SW | 1 |
| Raj, AB | 1 |
| Bertolone, SJ | 1 |
| Ochi, K | 1 |
| Daigo, Y | 1 |
| Katagiri, T | 1 |
| Nagayama, S | 1 |
| Tsunoda, T | 1 |
| Toyama, Y | 1 |
| Toguchida, J | 1 |
| Nakamura, Y | 1 |
| Zalupski, MM | 1 |
| Rankin, C | 1 |
| Ryan, JR | 1 |
| Lucas, DR | 1 |
| Muler, J | 1 |
| Lanier, KS | 1 |
| Budd, GT | 1 |
| Biermann, JS | 1 |
| Meyers, FJ | 1 |
| Antman, K | 2 |
| Crews, KR | 2 |
| Liu, T | 2 |
| Rodriguez-Galindo, C | 3 |
| Tan, M | 1 |
| Meyer, WH | 7 |
| Panetta, JC | 1 |
| Link, MP | 4 |
| Takahashi, S | 1 |
| Okada, K | 1 |
| Nagasawa, H | 1 |
| Shimada, Y | 1 |
| Sakamoto, H | 1 |
| Itoi, E | 1 |
| Patel, SR | 1 |
| Papadopolous, N | 1 |
| Raymond, AK | 2 |
| Donato, M | 1 |
| Seong, CM | 1 |
| Yasko, AW | 1 |
| Champlin, R | 1 |
| Benjamin, RS | 1 |
| Guo, W | 1 |
| Yang, RL | 1 |
| Tang, XD | 1 |
| Tang, S | 1 |
| Li, DS | 1 |
| Goto, T | 2 |
| Kosaku, H | 1 |
| Kobayashi, H | 1 |
| Hozumi, T | 2 |
| Kondo, T | 2 |
| Berrak, SG | 1 |
| Pearson, M | 1 |
| Berberoğlu, S | 1 |
| Ilhan, IE | 1 |
| Rawlins, JM | 1 |
| Batchelor, AG | 1 |
| Liddington, MI | 1 |
| Towns, G | 1 |
| Stewart, CF | 1 |
| Berta, M | 1 |
| Rapidis, AD | 1 |
| Gakiopoulou, H | 1 |
| Stavrianos, SD | 1 |
| Vilos, GA | 1 |
| Faratzis, G | 1 |
| Douzinas, EE | 1 |
| Givalos, N | 1 |
| Patsouris, E | 1 |
| Kleinerman, ES | 5 |
| Betcher, D | 2 |
| Conrad, E | 1 |
| Ferguson, W | 2 |
| Gebhardt, M | 1 |
| Harris, MB | 4 |
| Healey, J | 1 |
| Huvos, A | 1 |
| Link, M | 2 |
| Montebello, J | 1 |
| Nieder, M | 2 |
| Sato, J | 1 |
| Siegal, G | 1 |
| Weiner, M | 1 |
| Wells, R | 1 |
| Wold, L | 1 |
| Womer, R | 1 |
| Heymann, D | 1 |
| Ory, B | 1 |
| Blanchard, F | 1 |
| Heymann, MF | 1 |
| Coipeau, P | 1 |
| Charrier, C | 1 |
| Couillaud, S | 1 |
| Thiery, JP | 1 |
| Dinçbaş, FO | 1 |
| Koca, S | 1 |
| Mandel, NM | 1 |
| Hiz, M | 1 |
| Dervişoğlu, S | 1 |
| Seçmezacar, H | 1 |
| Oksüz, DC | 1 |
| Ceylaner, B | 1 |
| Uzel, B | 1 |
| Pieretti, F | 1 |
| Verri, E | 1 |
| Tolentinis, L | 1 |
| Versari, M | 4 |
| Zolezzi, C | 2 |
| Lamanna, G | 2 |
| Zak, D | 1 |
| Styler, MJ | 1 |
| Rosenbluth, JZ | 1 |
| Brodsky, I | 1 |
| Meyer, T | 1 |
| Michelagnoli, MP | 2 |
| Lewis, I | 1 |
| Eselgrim, M | 1 |
| Grunert, H | 1 |
| Bürger, H | 1 |
| Alvegard, TA | 2 |
| Bernini, G | 3 |
| Müller, C | 1 |
| Wiebe, T | 1 |
| Gordon, N | 1 |
| Arndt, CA | 2 |
| Hawkins, DS | 1 |
| Doherty, DK | 1 |
| Inwards, CY | 1 |
| Munsell, MF | 1 |
| Stewart, J | 1 |
| Koshkina, NV | 1 |
| McCarville, MB | 1 |
| Cain, AM | 1 |
| Duan, X | 1 |
| Jia, SF | 2 |
| Koshkina, N | 1 |
| Petrilli, AS | 1 |
| de Camargo, B | 1 |
| Filho, VO | 1 |
| Bruniera, P | 1 |
| Brunetto, AL | 1 |
| Jesus-Garcia, R | 1 |
| Camargo, OP | 1 |
| Pena, W | 1 |
| Péricles, P | 1 |
| Davi, A | 1 |
| Prospero, JD | 1 |
| Alves, MT | 1 |
| Oliveira, CR | 1 |
| Macedo, CR | 1 |
| Mendes, WL | 1 |
| Almeida, MT | 1 |
| Borsato, ML | 1 |
| dos Santos, TM | 1 |
| Ortega, J | 1 |
| Consentino, E | 1 |
| Moro, C | 1 |
| Taino, R | 1 |
| Mandalà, M | 1 |
| Labianca, R | 1 |
| Escobosa Sánchez, OM | 1 |
| Herrero Hernández, A | 1 |
| Ortega Acosta, MJ | 1 |
| Camacho Alonso, J | 1 |
| Milano Manso, G | 1 |
| Acha García, T | 1 |
| Anderson, P | 2 |
| Barbieri, E | 1 |
| Kalifa, C | 5 |
| Pichon, F | 1 |
| Vanel, D | 2 |
| Dupoüy, N | 1 |
| Takenaka, M | 1 |
| Okamoto, Y | 1 |
| Ikeda, K | 1 |
| Hashimoto, R | 1 |
| Kurokawa, N | 1 |
| Takagi, T | 1 |
| Uejima, E | 1 |
| Takahashi, K | 2 |
| Sakurai, K | 1 |
| Tanaka, H | 1 |
| Fujimoto, Y | 1 |
| Hung, MC | 1 |
| Lin, PC | 1 |
| Tiu, CM | 1 |
| Tien, YC | 1 |
| Okuma, T | 1 |
| Nakada, I | 1 |
| Basaran, M | 1 |
| Bavbek, ES | 1 |
| Saglam, S | 1 |
| Eralp, L | 1 |
| Sakar, B | 1 |
| Atalar, AC | 1 |
| Bilgic, B | 1 |
| Ozger, H | 1 |
| Onat, H | 1 |
| Mahajan, A | 1 |
| Woo, SY | 1 |
| Kornguth, DG | 1 |
| Hughes, D | 1 |
| Huh, W | 1 |
| Chang, EL | 1 |
| Herzog, CE | 1 |
| Pelloski, CE | 1 |
| Ferguson, WS | 3 |
| Harris, M | 1 |
| Kleinerman, E | 1 |
| Siegal, GP | 2 |
| Weiner, MA | 1 |
| Wells, RJ | 1 |
| Womer, RB | 2 |
| Thiele, OC | 1 |
| Freier, K | 1 |
| Bacon, C | 1 |
| Egerer, G | 1 |
| Hofele, CM | 1 |
| Takeuchi, S | 1 |
| Akahoshi, Y | 1 |
| Kasai, C | 1 |
| Nishimoto, Y | 1 |
| Canpolat, C | 1 |
| Pearson, P | 1 |
| Robertson, R | 1 |
| Küpfer, A | 1 |
| Aeschlimann, C | 1 |
| Wermuth, B | 1 |
| Cerny, T | 1 |
| Carpentier, AF | 1 |
| Chantelard, JV | 1 |
| Henin, D | 1 |
| Poisson, M | 1 |
| Gano, JB | 1 |
| Garcia, AA | 1 |
| Winkler, K | 6 |
| Delling, G | 5 |
| Delepine, N | 2 |
| Delepine, G | 2 |
| Desbois, JC | 1 |
| Razafindrakoto, H | 1 |
| Vassal, G | 1 |
| Contesso, G | 1 |
| Edeline, V | 1 |
| Valteau, D | 1 |
| Lemerle, J | 2 |
| Rodary, C | 1 |
| Raquin, M | 1 |
| Valteau-Couanet, D | 1 |
| Cantor, AB | 1 |
| Ayala, AG | 1 |
| Holbrook, T | 2 |
| Izraeli, S | 1 |
| Adamson, PC | 1 |
| Blaney, SM | 1 |
| Balis, FM | 1 |
| Elomaa, I | 1 |
| Pratt, CB | 4 |
| Parham, DM | 3 |
| Fleming, ID | 1 |
| Miser, JS | 1 |
| Pritchard, DJ | 1 |
| Rock, MG | 1 |
| Shives, TC | 1 |
| Gilchrist, GS | 1 |
| Smithson, WA | 1 |
| Edmonson, JH | 1 |
| Schaid, DJ | 1 |
| Schvartzman, E | 1 |
| Scopinaro, M | 1 |
| Muriel, FS | 1 |
| Rosen, G | 1 |
| Kjønniksen, I | 1 |
| Winderen, M | 1 |
| Bruland, O | 1 |
| Hartley, JM | 1 |
| Hansen, L | 1 |
| Harland, SJ | 1 |
| Nicholson, PW | 1 |
| Pasini, F | 1 |
| Souhami, RL | 2 |
| Fujinami, S | 1 |
| Nakaseko, K | 1 |
| Ogihara, Y | 1 |
| Kálmánchey, R | 1 |
| Koós, R | 1 |
| Majtényi, K | 1 |
| Borsi, J | 1 |
| Otsuka, T | 1 |
| Matsui, N | 1 |
| Ohta, H | 1 |
| Hattori, M | 1 |
| Nakamura, T | 1 |
| Umeda, T | 2 |
| Kitoh, M | 2 |
| Tatezaki, S | 2 |
| Satoh, T | 2 |
| Sassoli, V | 1 |
| Orlandi, M | 1 |
| Strazzari, S | 2 |
| Puggioli, C | 2 |
| Battistini, A | 1 |
| Lowry, PA | 1 |
| Carstens, C | 1 |
| Voûte, PA | 2 |
| van den Berg, H | 1 |
| Behrendt, H | 1 |
| Michiels, E | 1 |
| de Kraker, J | 1 |
| Roguin, A | 1 |
| Ben Arush, MW | 2 |
| Higasi, A | 1 |
| Kuten, A | 2 |
| Ferraro, A | 1 |
| Tella, G | 1 |
| Lokiec, F | 1 |
| Santoni, J | 1 |
| Weill, S | 1 |
| Tubiana-Hulin, M | 1 |
| Monti, C | 1 |
| Zanoni, A | 1 |
| Uchida, A | 1 |
| Shinto, Y | 1 |
| Brunat-Mentigny, M | 4 |
| Demaille, MC | 2 |
| Pein, F | 1 |
| Avet-Loiseau, H | 1 |
| Berger, C | 1 |
| De Lumley, L | 1 |
| Sariban, E | 1 |
| Pillon, P | 1 |
| Bernard, JL | 1 |
| Sottili, S | 1 |
| Gasbarrini, A | 2 |
| Campanacci, M | 4 |
| Chap, LI | 1 |
| Mirra, J | 1 |
| Ippolito, V | 1 |
| Rentschler, R | 1 |
| Rosen, P | 1 |
| Hirota, T | 1 |
| Takeuchi, M | 1 |
| Iwata, A | 1 |
| Kitagawa, S | 1 |
| Sato, T | 1 |
| Konno, K | 1 |
| Sawada, K | 1 |
| Kobayashi, S | 1 |
| Hamaguchi, N | 1 |
| Agata, H | 1 |
| Katano, N | 1 |
| Stein, ME | 1 |
| Moses, M | 1 |
| Drumea, K | 1 |
| Haim, N | 1 |
| Crowley, J | 1 |
| Balcerzak, SP | 1 |
| Kempf, RA | 1 |
| Weiss, RB | 1 |
| Clamon, GH | 1 |
| Baker, LH | 1 |
| Brach del Prever, A | 2 |
| McDonald, AR | 1 |
| Pogrel, MA | 1 |
| Sharma, A | 1 |
| Koch Nogueira, PC | 1 |
| Hadj-Aïssa, A | 1 |
| Schell, M | 1 |
| Cochat, P | 1 |
| Fuchs, N | 1 |
| Epler, D | 1 |
| Bieling, P | 2 |
| Körholz, D | 1 |
| Graf, N | 1 |
| Heise, U | 2 |
| Weinel, P | 2 |
| Werner, M | 1 |
| Gieser, P | 1 |
| Ayala, A | 1 |
| Lindner, NJ | 1 |
| Scarborough, MT | 1 |
| Spanier, SS | 1 |
| Enneking, WF | 1 |
| Whitin, JC | 1 |
| Tham, DM | 1 |
| Bhamre, S | 1 |
| Ornt, DB | 1 |
| Scandling, JD | 1 |
| Tune, BM | 1 |
| Salvatierra, O | 1 |
| Avissar, N | 1 |
| Cohen, HJ | 1 |
| Arndt, C | 1 |
| Morgenstern, B | 1 |
| Hawkins, D | 1 |
| Wilson, D | 1 |
| Liedtke, R | 1 |
| Miser, J | 1 |
| Miniero, R | 1 |
| Vassallo, E | 1 |
| Nesi, F | 1 |
| Busca, A | 1 |
| Albiani, R | 1 |
| Madon, E | 1 |
| Lewis, IJ | 1 |
| Gattamaneni, HR | 1 |
| Bailey, CC | 1 |
| Lashford, LS | 1 |
| Fasano, MC | 1 |
| Philip, T | 1 |
| Iliescu, C | 1 |
| Krakowski, I | 1 |
| Soler-Michel, P | 1 |
| Thiesse, P | 1 |
| Chauvin, F | 1 |
| Nooij, M | 1 |
| Somers, R | 1 |
| Cortés-Funes, H | 1 |
| van der Eijken, JW | 1 |
| Kirkpatrick, A | 1 |
| Uscinska, BM | 1 |
| van Glabbeke, M | 1 |
| Machin, D | 1 |
| Weeden, S | 1 |
| Simoni, P | 1 |
| Casadei, R | 1 |
| Poquette, CA | 1 |
| Marina, NM | 1 |
| Mahmoud, HH | 1 |
| Harper, J | 1 |
| Neel, M | 1 |
| Fletcher, BD | 2 |
| Zavatta, M | 1 |
| Fiorentini, G | 1 |
| Rimondini, S | 1 |
| De Giorgi, U | 1 |
| Campanacci, L | 1 |
| Biagini, R | 1 |
| Stewart, SL | 1 |
| Berend, KR | 1 |
| Pietrobon, R | 1 |
| Moore, JO | 1 |
| Dibernardo, L | 1 |
| Harrelson, JM | 1 |
| Scully, SP | 1 |
| Ito, T | 1 |
| Mochida, A | 1 |
| Saito, K | 1 |
| Nishi, K | 1 |
| Sasaki, S | 1 |
| Hisada, T | 1 |
| Morinari, H | 1 |
| Nakahara, K | 1 |
| Tahara, M | 1 |
| Masuda, S | 1 |
| Yakumaru, K | 1 |
| Lari, S | 1 |
| Marti, C | 2 |
| Steiner, R | 1 |
| Viollier, AF | 1 |
| Lelieveld, P | 1 |
| van Putten, LM | 1 |
| Estrada-Aguilar, J | 1 |
| Greenberg, H | 1 |
| Walling, A | 1 |
| Schroer, K | 1 |
| Black, T | 1 |
| Morse, S | 1 |
| Hvizdala, E | 1 |
| Antman, KH | 1 |
| Yasutake, H | 1 |
| Yokogawa, A | 1 |
| Baba, H | 1 |
| Ueda, Y | 1 |
| Tomita, K | 1 |
| Scher, CS | 1 |
| Amar, D | 1 |
| McDowall, RH | 1 |
| Barst, SM | 1 |
| Hanna, SL | 1 |
| Fairclough, DL | 1 |
| Le, AH | 1 |
| Avery, L | 1 |
| McKay, CP | 1 |
| Wyatt, RJ | 1 |
| Hancock, ML | 1 |
| Dose, C | 1 |
| Ritter, J | 3 |
| Petrilli, S | 1 |
| Penna, V | 1 |
| Lopes, A | 1 |
| Figueiredo, MT | 1 |
| Gentil, FC | 1 |
| Pignatti, G | 1 |
| De Cristofaro, R | 1 |
| Dallari, D | 1 |
| Avella, M | 1 |
| Marangolo, M | 1 |
| Ferruzzi, A | 1 |
| Fujita, H | 1 |
| Kiyokawa, N | 1 |
| Takada, K | 1 |
| Kyo, K | 1 |
| Ishimoto, K | 1 |
| Yabuta, K | 1 |
| Mizuno, T | 1 |
| Iwasaku-Fujimoto, M | 1 |
| Fujiwara, F | 1 |
| Todo, S | 1 |
| Morioka, Y | 1 |
| Imashuku, S | 1 |
| Dirix, LY | 2 |
| Van Oosterom, AT | 2 |
| Bührer, C | 1 |
| Sauter, S | 1 |
| Reiter, A | 1 |
| Riehm, H | 1 |
| Laszig, R | 1 |
| Greenshaw, C | 1 |
| Kusnierz-Glaz, C | 1 |
| Erttmann, R | 1 |
| Biron, P | 1 |
| Kohler, R | 1 |
| Blondet, R | 1 |
| Bérard, J | 1 |
| Chauvot, P | 1 |
| Bouffet, E | 1 |
| Carret, JP | 1 |
| Jonas, P | 1 |
| Patricot, LM | 1 |
| Purfürst, C | 1 |
| Eschenbach, C | 1 |
| Maroske, D | 1 |
| Taillard, F | 1 |
| Desbois, JG | 1 |
| Cornille, H | 1 |
| Jasmin, C | 1 |
| Horowitz, ME | 1 |
| Etcubanas, E | 1 |
| Thompson, EI | 1 |
| Douglass, EC | 1 |
| Wilimas, JA | 1 |
| Hayes, FA | 1 |
| Green, AA | 1 |
| Gasparini, M | 1 |
| Klein, HO | 1 |
| Dias Wickramanayake, P | 1 |
| Coerper, C | 1 |
| Christian, E | 1 |
| Kroner, T | 1 |
| Remagen, W | 1 |
| Berchtold, W | 1 |
| Cserhati, M | 1 |
| Varini, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination With Ifosfamide and Etoposide Versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults With Relapsed or Refractory Osteosa[NCT04154189] | Phase 2 | 81 participants (Actual) | Interventional | 2020-03-23 | Completed | ||
| Evaluation of Myocardial Injury After Anthracycline Chemotherapy in Osteosarcoma Patients Using CMR[NCT04461223] | 55 participants (Anticipated) | Observational [Patient Registry] | 2019-12-01 | Recruiting | |||
| A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy[NCT00134030] | Phase 3 | 1,334 participants (Actual) | Interventional | 2005-11-14 | Completed | ||
| OS2006 : Protocole de Traitement Des ostéosarcomes de l'Enfant, de l'Adolescent et de l'Adulte Comportant[NCT00470223] | Phase 3 | 318 participants (Actual) | Interventional | 2007-03-31 | Active, not recruiting | ||
| Multicenter Observational Study on the Treatment of Patients With Localized Osteosarcoma[NCT04890067] | 120 participants (Anticipated) | Observational | 2021-07-30 | Recruiting | |||
| Osteosarcoma 1999-A Study Of Intensive Chemotherapy Utilizing Ifosfamide, Carboplatin, and Doxorubicin for Adjuvant Chemotherapy for Treatment of Osteosarcoma[NCT00145639] | Phase 2 | 80 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study[NCT03737435] | 80 participants (Anticipated) | Observational | 2018-12-12 | Recruiting | |||
| A Phase I Trial and Pharmacokinetic Study of the Oral Platinum Analog Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors[NCT01259479] | Phase 1 | 9 participants (Actual) | Interventional | 2010-12-03 | Completed | ||
| SFOP-OS94: Multicentric Randomised Phase III Trial Comparing Efficacy of Preoperative High-Dose Methotrexate Plus Doxorubicin to Efficacy of High-Dose Methotrexate Plus Etoposide and Ifosfamide, in Children and Adolescents Osteosarcoma[NCT00180908] | Phase 3 | 226 participants | Interventional | 1994-06-30 | Completed | ||
| MISTOSUS: Iscador® P (Mistletoe) Immunotherapy To Improve Event Free Survival In Patients With Relapsed Osteosarcoma After Resection Of Pulmonary Metastases[NCT05726383] | Phase 2 | 32 participants (Anticipated) | Interventional | 2023-12-15 | Not yet recruiting | ||
| Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471] | Phase 2 | 44 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Health-Related Quality of Life (HRQoL): PedsQL 4.0 Generic Core Scale is a multidimensional scale. It included assessment of 4 dimensions: physical functioning (8 items), emotional functioning (8 items), social functioning (8 items), and school functioning (5 items - children greater than or equal to [>=] 5 years, adults; 3 items - toddlers [aged 2-4 years]). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Generic Core Scale total score: sum of all the items divided by the number of items answered across all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Baseline and Month 4
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 2.61 |
| Treatment Arm B: Ifosfamide + Etoposide | 2.65 |
HRQoL: PedsQL 3.0 Cancer Module Scale measured pediatric cancer-specific HRQoL. It included assessment of 8 dimensions: pain and hurt (2 items), nausea (5 items), procedural anxiety (3 items), treatment anxiety (3 items), worry (3 items), cognitive problems (3 items - toddlers [aged 2-4], 4 items - young children [aged 5-7]; 5 items for children aged >=8 years, adults), perceived physical appearance (3 items), communication (3 items). Each item was reported using a 5-point Likert scale, items were then reverse-scored and linearly transformed to a 0 to 100 scale. Cancer Module total score: sum of all items divided by the number of items answered on all the scales. Total score ranges from 0 to 100, where higher scores=better HRQoL, lower scores=worse HRQoL. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Baseline and Month 4
| Intervention | score on a scale (Mean) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 2.66 |
| Treatment Arm B: Ifosfamide + Etoposide | 2.08 |
ORR-4m was defined as the percentage of participants with best overall response of complete response (CR) or partial response (PR) as determined by IIR using RECIST v1.1 within the first 4 months. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to less than (<) 10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% confidence interval (CI) of ORR was calculated using the method of Clopper and Pearson. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 4
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 15.0 |
| Treatment Arm B: Ifosfamide + Etoposide | 7.3 |
ORR by IIR was defined as the percentage of participants with best overall response of CR or PR determined using RECIST v1.1. CR: defined as the disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis to <10 mm. PR: defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. 95% CI of ORR was calculated using the method of Clopper and Pearson. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: From the date of randomization to the date of the first documentation of CR or PR, whichever occurred first (up to approximately 14.2 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 15.0 |
| Treatment Arm B: Ifosfamide + Etoposide | 9.8 |
OS-1y was defined as the time from the date of randomization to the date of death from any cause assessed up to 1 year. OS was calculated using the Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 12 or 1 Year
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 49.2 |
| Treatment Arm B: Ifosfamide + Etoposide | 72.1 |
PFS-1y rate as assessed by IIR was defined as the percentage of participants who were alive and without PD at 1 year from randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS-1y rate was estimated using Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 12 or 1 Year
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | NA |
| Treatment Arm B: Ifosfamide + Etoposide | 14.9 |
PFS rate at 4 months as assessed by IIR was defined as the percentage of participants who were alive and without PD at 4 months from the randomization date using RECIST v1.1. PD was defined as at least a 20% increase or 5 mm increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. The PFS-4m was estimated using the Kaplan-Meier method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Month 4
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 76.3 |
| Treatment Arm B: Ifosfamide + Etoposide | 66.0 |
PFS as assessed by IIR was defined as the time from the date of randomization to the date of the first documentation of PD or date of death (whichever occurred first), as determined using RECIST v1.1. PD was defined as at least a 20 percent (%) increase or 5 millimeter (mm) increase in the sum of diameters of target lesions (taking as reference the smallest sum on study) recorded since the treatment started or the appearance of 1 or more new lesions. PFS was analyzed using Kaplan-Meier method. (NCT04154189)
Timeframe: From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first (up to 14.2 months)
| Intervention | months (Median) |
|---|---|
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 6.5 |
| Treatment Arm B: Ifosfamide + Etoposide | 5.5 |
The palatability and acceptability of lenvatinib oral suspension formulation was assessed using the Palatability Questionnaire. In the questionnaire, participants were asked to answer palatability and acceptability of lenvatinib suspension considering the following elements: taste, appearance, smell, how does it feel in the mouth and overall acceptability in terms of 7 responses: Super good, really good, good, may be good or may be bad, bad, really bad, super bad. In this outcome measure, number of participants have been reported per their overall palatability and acceptability responses. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Cycle 1 Day 1 (Cycle length = 21 days)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Super Bad | Really Bad | Bad | May be Good or May be Bad | Good | Really Good | Super Good | |
| All Participants: Lenvatinib 14 mg/m^2 | 0 | 0 | 0 | 2 | 2 | 0 | 1 |
Plasma concentration of lenvatinib in participants from Treatment Arm A (Lenvatinib + Ifosfamide + Etoposide) at different time points were reported. As planned, data for this outcome measure was analyzed for treatment arm A only. Lenvatinib concentration in plasma was quantified using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Final analysis data was reported for this outcome measure. (NCT04154189)
Timeframe: Cycle 1 Day 1: 0.5-4 hours and 6-10 hours post-dose; Cycle 1 Day 15: Pre-dose, 0.5-4 hours and 6-10 hours post-dose; Cycle 2 Day 1: Pre-dose (each Cycle length = 21 days)
| Intervention | nanograms per milliliter (ng/mL) (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 1, Day 1: 0.5-4 hours post-dose | Cycle 1, Day 1: 6-10 hours post-dose | Cycle 1, Day 15: Pre-dose | Cycle 1, Day 15: 0.5-4 hours post-dose | Cycle 1, Day 15: 6-10 hours post-dose | Cycle 2, Day 1: Pre-dose | |
| Treatment Arm A: Lenvatinib + Ifosfamide + Etoposide | 147.9 | 217.8 | 70.7 | 222.3 | 310.9 | 70.2 |
"EFS is defined as time from randomisation to the first of: death, detection of local recurrence or metastasis, progression of metastatic disease, or detection of a secondary malignancy.~EFS will be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals. Follow up per participant will be assessed for up to 10 years. The 3 year EFS is provided as a summary." (NCT00134030)
Timeframe: From date of randomization to date of the event.
| Intervention | Percentage EFS (Number) |
|---|---|
| MAP-GR | 74 |
| MAPifn | 77 |
| MAP-PR | 55 |
| MAPIE | 53 |
"Overall survival is time from randomization until death from any cause.~Will be assessed using the logrank test and expressed using hazard ratios with appropriate confidence intervals. Participants will be assessed for up to 10 years. 5 year overall survival is provided as a summary." (NCT00134030)
Timeframe: From date of randomization to date of death.
| Intervention | Percentage of participants (Number) |
|---|---|
| MAP-GR | 84 |
| MAPifn | 84 |
| MAP-PR | 68 |
| MAPIE | 68 |
Percentages of patients experiencing grade 3 and 4 adverse events. These will be compared using chi-square tests or Fisher's exact tests where appropriate. (NCT00134030)
Timeframe: Adverse events are assessed for up to 10 years per participant.
| Intervention | Participants (Count of Participants) |
|---|---|
| MAP-GR | 348 |
| MAPifn | 340 |
| MAP-PR | 287 |
| MAPIE | 281 |
37 reviews available for ifosfamide and Osteogenic Sarcoma
| Article | Year |
|---|---|
Tumor lysis syndrome following ifosfamide monotherapy in metastatic osteosarcoma: a case report and review of the literature.
Topics: Bone Neoplasms; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Neoplasms, Second Primary; Osteosa | 2022 |
The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Do | 2020 |
Recurrent primary cardiac osteosarcoma: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Fatal Outcome; Heart | 2014 |
Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Cohort | 2014 |
Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C | 2014 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Doc | 2014 |
Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Ifosfamide; Neoadjuvant Ther | 2015 |
An update on chemotherapy for osteosarcoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Clinical Tri | 2015 |
Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Humans; Ifosf | 2015 |
Radiation-induced osteosarcoma of the skull base after radiation therapy in a patient with nasopharyngeal carcinoma: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Diplopia; Doxorubicin; | 2016 |
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; H | 2010 |
Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand?
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad | 2011 |
Isolated subcutaneous metastasis of osteosarcoma 5 years after initial diagnosis.
Topics: Abdominal Wall; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2011 |
The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; C | 2012 |
Advanced therapeutic strategy for radiation-induced osteosarcoma in the skull base: a case report and review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality T | 2012 |
A chemosensitive pediatric extraosseous osteosarcoma: case report and review of the literature.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Doxorubicin; Female; Human | 2003 |
Ifosfamide in pediatric solid tumors.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf | 2003 |
Palliative treatment for advanced or metastatic osteosarcoma.
Topics: Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A | 2004 |
Osteosarcoma occurring in osteogenesis imperfecta.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2004 |
[Soft tissue sarcoma: postoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Cyclophos | 2004 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Mo | 2005 |
Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; H | 2006 |
[Neoadjuvant treatment in osteosarcomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2006 |
Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemotherapy, Adjuvant; | 2007 |
Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chemoth | 1995 |
Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemotherapy, Adjuvant; C | 1993 |
An update of Scandinavian studies of osteosarcoma.
Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 1993 |
Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.
Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Th | 1993 |
Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child | 1993 |
Results of therapy in osteosarcoma: experience in childrens hospitals in Buenos Aires.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Neoplasms; Chemotherapy, Adjuvant; C | 1993 |
An opinion supporting the role of high-dose methotrexate in the treatment of osteosarcoma.
Topics: Acidosis, Renal Tubular; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap | 1993 |
Problems and controversies in the management of childhood sarcomas.
Topics: Amputation, Surgical; Antineoplastic Agents; Child; Child, Preschool; Doxorubicin; Humans; Ifosfamid | 1996 |
Chemotherapy of advanced sarcomas of bone and soft tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Dacarbazin | 1992 |
Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Austria; Bleomycin; Bone Neoplasm | 1991 |
The role of ifosfamide in the treatment of adult soft tissue sarcomas, Ewing's sarcoma, and osteosarcoma: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sarcoma, | 1990 |
The role of ifosfamide in the treatment of sarcomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Osteosarcoma; Sarcoma; Sa | 1989 |
65 trials available for ifosfamide and Osteogenic Sarcoma
| Article | Year |
|---|---|
OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Etoposide; | 2021 |
Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2017 |
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2018 |
Significance of neoadjuvant chemotherapy (NACT) in limb salvage treatment of osteosarcoma and its effect on GLS1 expression.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms | 2018 |
Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; | 2020 |
Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2013 |
Treatment of large osteosarcoma in children: new approach.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Doxoru | 2013 |
High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2014 |
Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2015 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherap | 2014 |
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-Response | 2015 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud | 2016 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud | 2016 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud | 2016 |
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Case-Control Stud | 2016 |
Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 2009 |
Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chil | 2009 |
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality | 2009 |
[Treatment of relapsed osteosarcoma. Role of chemotherapy using ifosamide and carboplatin].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chem | 2010 |
Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma.
Topics: Adolescent; Adult; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers; Child; Child, Preschool; | 2010 |
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil | 2011 |
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2012 |
Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Histi | 2002 |
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child; Child | 2003 |
Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of Cisplatin-Doxorubicin and high-dose Ifosfamide over 48, 24, and 120 hours.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Com | 2003 |
Adjuvant therapy of osteosarcoma--A Phase II trial: Southwest Oncology Group study 9139.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap | 2004 |
High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Topics: Adolescent; Adult; Age Factors; Antimetabolites, Antineoplastic; Bone Neoplasms; Child; Child, Presc | 2004 |
A phase II study of cisplatin, doxorubicin, and ifosfamide with peripheral blood stem cell support in patients with skeletal osteosarcoma and variant bone tumors with a poor prognosis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diseas | 2004 |
Effect of fractionated ifosfamide on the pharmacokinetics of irinotecan in pediatric patients with osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; D | 2004 |
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2005 |
Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols | 2005 |
A phase I/II study of doxorubicin, ifosfamide, etoposide and interval methotrexate in patients with poor prognosis osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2006 |
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2005 |
Metastatic osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil | 2006 |
Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival.
Topics: Adolescent; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Br | 2006 |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2007 |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2007 |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2007 |
SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2007 |
A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Epirub | 2007 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2008 |
Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic C | 1995 |
Chemotherapy in osteogenic sarcoma: the experience of the Pediatric Department of the Gustave Roussy Institute.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemot | 1993 |
Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Child; Clinical Trials, Phase II as Topic; Female; Humans; Ifosfamide; Male; Neop | 1995 |
An update of Scandinavian studies of osteosarcoma.
Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 1993 |
Osteosarcoma studies at St. Jude Children's Research Hospital from 1968 through 1990.
Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Th | 1993 |
Osteosarcoma in adolescents and young adults: new developments and controversies. The Mayo Clinic studies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child | 1993 |
Results of therapy in osteosarcoma: experience in childrens hospitals in Buenos Aires.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Bone Neoplasms; Chemotherapy, Adjuvant; C | 1993 |
Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. results of a randomized study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxoru | 1996 |
Phenobarbital administration does not affect high-dose ifosfamide pharmacokinetics in humans.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, High Pressur | 1996 |
Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Etoposide; | 1997 |
Neoadjuvant chemotherapy in malignant fibrous histiocytoma of bone and in osteosarcoma located in the extremities: analogies and differences between the two tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy | 1997 |
A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 1998 |
Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chem | 1998 |
Long-term nephrotoxicity of cisplatin, ifosfamide, and methotrexate in osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1998 |
Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child, Presc | 1998 |
Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combined Mo | 1998 |
Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1998 |
Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma.
Topics: Adolescent; Antineoplastic Agents; Carboplatin; Child; Dose-Response Relationship, Drug; Etoposide; | 1998 |
Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adult patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 1999 |
High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société F
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1999 |
A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Combined Modali | 1999 |
Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions.
Topics: Acute Disease; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone | 2000 |
Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2000 |
A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2001 |
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr | 2002 |
High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chondrocytes; Cis | 2002 |
Effect of chemotherapy combined with caffeine for osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Caffeine; Calcane | 1992 |
Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Austria; Bleomycin; Bone Neoplasm | 1991 |
Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda | 1990 |
Intensified chemotherapy with ifosfamide (IFO) and influence of intraarterial (i.a.) versus intravenous (i.v.) infusion of cisplatinum (DDP). Preliminary results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Humans; Ifosfamide; Infus | 1990 |
164 other studies available for ifosfamide and Osteogenic Sarcoma
| Article | Year |
|---|---|
A Retrospective Comparative Analysis of Outcomes and Prognostic Factors in Adult and Pediatric Patients with Osteosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Humans; Ifosfamide; Os | 2021 |
Management of elderly patients with bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Humans; Ifosfamid | 2022 |
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2022 |
Osteosarcoma and causes of death: A report of 1520 deceased patients from the Cooperative Osteosarcoma Study Group (COSS).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cause of Death; Cisplati | 2022 |
Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Heterografts | 2023 |
Outcomes and survival rates of childhood osteosarcoma in Iran, A report from MAHAK Pediatric Cancer Treatment and Research Center, from 2007 to 2020.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 2023 |
Total Neoadjuvant vs. Standard Perioperative Cisplatin/ Doxorubicin Chemotherapy in Patients with Extremities Osteosarcoma: A Multi-Center Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Extremities; | 2023 |
Clinical factors affecting prognosis of limb osteosarcoma in China: a multicenter retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chin | 2020 |
IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Cost-B | 2021 |
Ifosfamide induced encephalopathy in a child with osteosarcoma.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Female; Humans; Ifosf | 2021 |
Immunotherapy for osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Humans; Ifosfamide; Immunotherapy; | 2021 |
The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Child; Child, Presc | 2021 |
Chronic kidney disease consecutive to chemotherapy for chondroblastic osteosarcoma: A report on 6 pediatric cases.
Topics: Adolescent; Bone Neoplasms; Child; Humans; Ifosfamide; Osteosarcoma; Renal Insufficiency, Chronic; R | 2021 |
Adjuvant and neoadjuvant chemotherapy for osteosarcoma: JCOG Bone and Soft Tissue Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2021 |
Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2017 |
Transition from Tumor Tissue to Bone Marrow in Patients with Appendicular Osteosarcoma after Neoadjuvant Chemotherapy.
Topics: Adolescent; Adult; Bone Marrow; Bone Neoplasms; Child; Cisplatin; Doxorubicin; Female; Humans; Ifosf | 2017 |
Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Topics: Adolescent; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2017 |
Possible role of CYP2B6 genetic polymorphisms in ifosfamide-induced encephalopathy: report of three cases.
Topics: Administration, Intravenous; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Di | 2018 |
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Endostatins; Etoposide; Human | 2017 |
Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cardiotoxicity; Dimethyl Sulf | 2019 |
Prognostic implication of adjuvant/neoadjuvant chemotherapy consisting of doxorubicin and ifosfamide in patients with extraskeletal osteosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2019 |
Osteosarcoma journey over two decades in India: Small steps, big changes.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2019 |
Metastasis of osteosarcoma to stomach made clinically evident by hematemesis: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Combin | 2013 |
Osteosarcoma around the knee treated with neoadjuvant chemotherapy and a custom-designed prosthesis.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arthroplasty, Replacement, Knee; | 2013 |
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2013 |
Effects of blood purification therapy on a patient with ifosfamide-induced neurotoxicity and acute kidney injury.
Topics: Acute Kidney Injury; Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Female; Hemodiaf | 2014 |
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Female; Hearing Loss; Huma | 2014 |
Extraskeletal Osteosarcoma: An International Rare Cancer Network Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoc | 2016 |
[Value of ifosfamide in neoadjuvant therapy for osteosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2013 |
Is it important to maintain high-dose intensity chemotherapy in the treatment of adults with osteosarcoma?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-R | 2014 |
Reticulated hyperpigmentation following chemotherapy for radiation-induced osteosarcoma.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Etoposide; | 2014 |
Secondary malignant neoplasms after osteosarcoma: early onset and cumulative alkylating agent dose dependency.
Topics: Adolescent; Adult; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms | 2015 |
Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 2014 |
Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2015 |
Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Topics: Activation, Metabolic; Antineoplastic Agents, Alkylating; Bone Neoplasms; Cell Line, Tumor; Cell Sur | 2015 |
Ifosfamide-containing regimens for treating patients with osteosarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Epirubicin; F | 2014 |
Excision repair cross-complementation group 1 protein expression predicts survival in patients with high-grade, non-metastatic osteosarcoma treated with neoadjuvant chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfam | 2015 |
Development of tumor-specific caffeine-potentiated chemotherapy using a novel drug delivery system with Span 80 nano-vesicles.
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzoates; Bone | 2015 |
Continuous-infusion ifosfamide and doxorubicin combination as second-line chemotherapy for recurrent or refractory osteosarcoma patients in China: a retrospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; China; Dox | 2015 |
Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2015 |
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combin | 2015 |
Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cardiotonic Agents; Chil | 2016 |
Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Bone Neoplasms; Caspase 3; Cell Line, Tumor; | 2015 |
Singapore Cancer Network (SCAN) Guidelines for the Initial Evaluation, Diagnosis, and Management of Extremity Soft Tissue Sarcoma and Osteosarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Chemotherapy, Adjuvan | 2015 |
Marriage and fertility in long-term survivors of childhood, adolescent and young adult (AYA) high-grade sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2016 |
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms | 2016 |
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Cisplatin; Combined Modality The | 2017 |
[Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Diseases; Ch | 2017 |
Osteosarcoma: the same old drugs or more?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifos | 2008 |
Osteosarcoma in a patient with xeroderma pigmentosum.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy | 2009 |
Epithelioid osteosarcoma of the jaw.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Doxorubicin; Epithelioid Cells; Fe | 2009 |
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma.
Topics: Animals; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; DNA Primers; Drug Resistance, Neopl | 2009 |
An osteoporotic hip fracture in a 14-year-old girl undergoing chemotherapy and operated for knee osteosarcoma.
Topics: Adolescent; Antineoplastic Agents; Arthroplasty, Replacement, Knee; Bone Neoplasms; Chemotherapy, Ad | 2009 |
Late effects surveillance system after childhood cancer in Germany, austria and parts of Switzerland--update 2009.
Topics: Adolescent; Aftercare; Antineoplastic Combined Chemotherapy Protocols; Austria; Bone Neoplasms; Card | 2009 |
Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Disease Progression; Female; Ifosfamide; Immunotherapy; I | 2009 |
Long-term evaluation of Ifosfamide-related nephrotoxicity in children.
Topics: Antineoplastic Agents, Alkylating; Child; Follow-Up Studies; Humans; Ifosfamide; Kidney; Kidney Dise | 2009 |
Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.
Topics: Animals; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor | 2009 |
Ifosfamide-induced encephalopathy and movement disorder.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Bone Neoplasms; Brain Diseases; Child; Female; Humans | 2010 |
Therapeutic effect of pirarubicin-based chemotherapy for osteosarcoma patients with lung metastasis.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Membe | 2010 |
Moyamoya in a child treated with interferon for recurrent osteosarcoma.
Topics: Antineoplastic Agents; Bone Neoplasms; Carotid Artery Diseases; Cerebral Arterial Diseases; Cerebral | 2010 |
Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Disease Models, Animal | 2011 |
Magnetic resonance imaging is appropriate for determining the osteotomy plane for appendicular osteosarcoma after neoadjuvant chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2012 |
Metastatic osteosarcoma presenting as a single pulmonary microembolus.
Topics: Adolescent; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therap | 2011 |
Relationship between hypermethylated MGMT gene and osteosarcoma necrosis rate after chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2011 |
Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma: 63 patients with a minimum follow-up of 4 years.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemo | 2011 |
Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2011 |
Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2011 |
Extraskeletal osteosarcoma of the breast in an adolescent girl.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Chemot | 2012 |
Maintenance therapy in the treatment of sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Disease-Free Survival; Doxorubicin; Humans; Ifosfam | 2011 |
Small cell osteosarcoma successfully treated by high-dose ifosfamide and methotrexate, combined with carboplatin and pirarubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherapy, Adjuvant; | 2012 |
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytid | 2013 |
Ifosfamide in the neoadjuvant treatment of osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; D | 2012 |
[Organ-preserving interventions in combined therapy of children and adolescents with osteosarcoma].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Transplantation; Ch | 2012 |
Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bone Neoplasm | 2013 |
Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2014 |
Osteosarcoma of the pelvis: a monoinstitutional experience in patients younger than 41 years.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2012 |
A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; C | 2002 |
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arm; ATP Binding Cassette T | 2003 |
Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2003 |
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil | 2003 |
Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-Response | 2003 |
Preoperative therapy versus immediate surgery in nonmetastatic osteosarcoma.
Topics: Amputation, Surgical; Bone Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Humans; Ifosfa | 2003 |
Ovarian toxicity after chemotherapy: possible association with ifosfamide administration.
Topics: Adolescent; Adult; Antineoplastic Agents; Female; Hot Flashes; Humans; Ifosfamide; Menstruation Dist | 2004 |
Methylene blue reversal of ifosfamide-related encephalopathy.
Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Electroencephalography; Enzyme Inhibitors; | 2004 |
Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2004 |
[Neoadjuvant chemotherapy for osteosarcoma].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2004 |
[Goal and results of the COSS study].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Chemotherapy | 2004 |
High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
Topics: Adolescent; Adult; Bone Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Female; Hu | 2005 |
Tumor excision and reconstruction of the upper cervical spine: a multidisciplinary approach.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axis, Cervical Vertebra; Bone Transplantation | 2004 |
Long-term survival in high-grade axial osteosarcoma with bone and lung metastases treated with chemotherapy only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Child, Preschool; Cispl | 2005 |
Sarcomas of the head and neck. Results from the treatment of 25 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2005 |
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Caspases; Cell Line, Tumor | 2005 |
The role of preoperative radiotherapy in nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery.
Topics: Adolescent; Adult; Aged; Amputation, Surgical; Analysis of Variance; Antineoplastic Combined Chemoth | 2005 |
Prospective evaluation of renal function in pediatric and adult patients treated with high-dose ifosfamide, cisplatin and high-dose methotrexate.
Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas | 2005 |
Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2006 |
Fas expression in lung metastasis from osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2005 |
Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Combined Mod | 2006 |
Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy.
Topics: Acute Disease; Adult; Analgesics, Opioid; Antineoplastic Agents, Alkylating; Buprenorphine; Humans; | 2006 |
Clearance of methotrexate by means of hemofiltration in a patient with osteosarcoma.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplati | 2006 |
Neoadjuvant chemotherapy for radioinduced osteosarcoma of the extremity: The Rizzoli experience in 20 cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adj | 2007 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2007 |
Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde.
Topics: Acetaldehyde; Adenosine Triphosphate; Annexin A5; Antineoplastic Agents, Alkylating; Blotting, Weste | 2007 |
Acute pancreatitis associated with ifosfamide.
Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Humans; Ifosfamide; Male; O | 2007 |
Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999.
Topics: Adult; Amputation, Surgical; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Bone Ne | 2007 |
Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combin | 2007 |
[Preoperative adjuvant therapy for primary malignant bone tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomycin; Doxo | 2007 |
Multimodality treatment of osteosarcoma: radiation in a high-risk cohort.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2008 |
Interdisciplinary combined treatment of craniofacial osteosarcoma with neoadjuvant and adjuvant chemotherapy and excision of the tumour: a retrospective study.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti | 2008 |
[Clinical evaluation on the sensitivity test for anti-cancer agents in malignant bone and soft-tissue tumors].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; | 1984 |
Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Blood; Bone Marrow; Bone Neopl | 1996 |
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue.
Topics: Administration, Oral; Adolescent; Antidotes; Bone Neoplasms; Brain Diseases; Drug Overdose; Female; | 1994 |
Osteosarcoma following radiation treatment for meningioma: report of a case and effective treatment with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Cisplatin; Dacti | 1994 |
Ifosfamide-induced Fanconi syndrome.
Topics: Adult; Bone Neoplasms; Fanconi Syndrome; Humans; Ifosfamide; Male; Osteomalacia; Osteosarcoma | 1995 |
A monocentric therapy study: an approach to optimize the results of the treatment of osteosarcoma by protocols based upon HDMTX, associated with systematic conservative surgery.
Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bo | 1993 |
Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1994 |
Acute pancreatitis after ifosfamide therapy.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; H | 1994 |
Validity and usefulness of human tumor models established by intratibial cell inoculation in nude rats.
Topics: Animals; Bone Neoplasms; Cell Line; Doxorubicin; Female; Femur; Ifosfamide; Male; Melanoma, Amelanot | 1994 |
Metabolism of ifosfamide during a 3 day infusion.
Topics: Adenocarcinoma; Chromatography, Thin Layer; Female; Humans; Ifosfamide; Male; Neuroectodermal Tumors | 1994 |
[Chemotherapy for osteosarcoma--trends in recent years].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Ci | 1993 |
Wernicke-encephalopathy in children with cancer.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Moda | 1994 |
Osteosarcoma with deeply eosinophilic rhabdomyoblast cells in a lung metastatic focus. A case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Femoral Neoplasms; | 1993 |
[Toxic effects of ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Administration, Intravesical; Adolescent; Adult; Aluminum Hydroxide; Bone Neoplasms; Child, Preschoo | 1993 |
Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Ci | 1993 |
Intense gallbladder uptake associated with chemotherapy. An unusual finding in pediatric skeletal scintigraphy.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; B | 1995 |
Ifosfamide in the treatment of pediatric malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 1996 |
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C | 1996 |
Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Di | 1997 |
Neoadjuvant chemotherapy for pediatric osteosarcoma patients.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 1997 |
Neoadjuvant chemotherapy for osseous malignant fibrous histiocytoma of the extremity: results in 18 cases and comparison with 112 contemporary osteosarcoma patients treated with the same chemotherapy regimen.
Topics: Adolescent; Adult; Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti | 1997 |
Miliary osteosarcomatosis with associated hypocalcemia.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antine | 1997 |
[The effects of high-dose ifosfamide in the treatment of bone and soft tissue sarcomas].
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Drug Administration Sch | 1997 |
[Pilot study of relapsed osteosarcoma and brain tumor with ifosfamide, carboplatin and etoposide (ICE therapy)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; | 1998 |
Postsurgical etoposide-ifosfamide regimen in poor-risk nonmetastatic osteogenic sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr | 1998 |
Neoadjuvant chemotherapy for extremity osteosarcoma--preliminary results of the Rizzoli's 4th study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherap | 1998 |
Effects of chemotherapy on osseointegration of implants: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Transplantation; Cisplatin; Dacarbazine; | 1998 |
Plasma glutathione peroxidase and its relationship to renal proximal tubule function.
Topics: Adult; Animals; Antibodies; Cephaloglycin; Child; Creatinine; Fanconi Syndrome; Glutathione Peroxida | 1998 |
Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1999 |
Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Drug Administrati | 1999 |
Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chil | 2001 |
Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxoru | 2001 |
Histologic response of high-grade nonmetastatic osteosarcoma of the extremity to chemotherapy,.
Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neopla | 2001 |
Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 2001 |
Postchemotherapy confusion.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Humans; Ifosfamide; M | 2001 |
Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection.
Topics: Adolescent; Adult; Aged; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; | 2002 |
[High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
Topics: Adult; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Oste | 1979 |
Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Topics: Acrolein; Animals; Antineoplastic Agents; Biotransformation; Cells, Cultured; Cyclophosphamide; Dose | 1976 |
Primary treatment of pelvic osteosarcoma. Report of five cases.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Neoplasms; Chemot | 1992 |
Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Female; Hum | 1992 |
Assessment of osteosarcoma response to preoperative chemotherapy using dynamic FLASH gadolinium-DTPA-enhanced magnetic resonance mapping.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; | 1992 |
Ifosfamide, Fanconi's syndrome, and rickets.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Chronic Kidney Disease-Mineral an | 1991 |
IIB osteosarcoma. Current management, local control, and survival statistics--São Paulo, Brazil.
Topics: Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brazil; Cispla | 1991 |
Neoadjuvant chemotherapy for nonmetastatic osteosarcoma of the extremities.
Topics: Adolescent; Adult; Amputation, Surgical; Antineoplastic Combined Chemotherapy Protocols; Bone Length | 1991 |
[Successful treatment of metastatic and refractory osteosarcoma by ifosfamide, carboplatin and vindesine: case report].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Drug Admini | 1991 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |
Acute onset deafness in a 4-year-old girl after a single infusion of cis-platinum.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cisplatin; Combined | 1990 |
[Developments in the treatment of osteosarcoma since 1979. Report of the statistics at the Centre Léon-Bérard].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; | 1990 |
[Successful treatment of several metachronous pulmonary metastases of a chondroblastic osteosarcoma].
Topics: Amputation, Surgical; Bleomycin; Child; Chondroblastoma; Cyclophosphamide; Dactinomycin; Female; Hum | 1985 |
CNS-side effects induced by Ifosfamide-Mesna in children with osteosarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Central Nervous System D | 1986 |
Phase II trial of ifosfamide in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Eva | 1987 |
High-dose ifosfamide alone and in combination for solid malignancies in childhood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Humans; Ifosfamide; Mesna; Nausea; | 1986 |
Treatment of advanced soft tissue and osteogenic sarcomas with continuous infusion of ifosfamide and mesna.
Topics: Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Mercaptoethanol; Mesna; Middle Aged; Osteo | 1986 |
High-dose ifosfamide in advanced osteosarcoma.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Humans; Ifosfamide; Nausea; Osteosarcoma; Prospective Studi | 1985 |